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The incidence of esophageal adenocarcinoma (EAC) has been rising at an alarming rate 
over the past three decades (>450-fold). Identification of patients with the metaplastic condition 
termed Barrett’s esophagus (BE), is a risk factor for the development of EAC, yet allows patients 
to undergo endoscopic surveillance biopsy to help detect cancer. Our group and others have 
identified markers that can potentially identify high-grade dysplasia (HGD) and/or EAC in BE 
patients. However, we have observed that >30% of patients with cancers at the gastroesophageal 
junction (GEJ) have no previous history of BE. These cancers are also similarly increasing in 
incidence thus new approaches are also needed for these patients. Interestingly, the increasing 
incidence of EAC primarily affects the Caucasian population as compared to the African 
American (AA) population. Therefore, in this thesis we aim to understand: 1) whether EAC 
vs. tumors located at the GEJ are molecularly distinct, 2a) the characterization of 
molecular events at the transcriptome level associated with the progression from non-
dysplastic BE to dysplasia to cancer 2b) as well as biomarkers that identify patients that 
are at greatest risk for development of EAC and 3) understanding the basis for the 
difference in the incidence of EAC between CAU and AA. We were able to show that EAC 
and GEJAC tumors are molecularly similar, and identified cell surface markers that can be used 
to detect both non-BE derived GEJs and EACs. Using transcriptional analysis of BE, dysplasia, 
and EAC we identified splicing has a key dysregulated pathway in BE progression. In addition, 
we observed an increase in the ATM/DNA-response damage in this progression that, we assume, 




event that reduces the expression of the detoxifying enzyme GSTT2 in the esophagus of Cau 
populations as compared to AA populations. This body of work adds to our understanding of 
molecular events in EAC and GEJ and could potentially impact the way we diagnose and treat 





































Introduction: Esophageal Cancers; Incidence, Histology, Treatment, and Progression 
 
Esophageal Cancer 
Cancer is the second leading cause of death in the United States (US), with 14.1 million 
new cases diagnosed globally1.  In the US, approximately 42% of all cancers cases in men are 
related to prostate, lung, and colorectal cancers. Similarly, women’s most common cancers 
diagnose include breast, lung, and colorectal1. In contrast, esophageal cancers (EC) are not 
common, with approximately 16,940 new cases diagnosed in 20171. Nevertheless, EC are a 
significant worldwide health problem because of their poor prognosis1,2, and they are the seventh 
leading cause of death in men when compared to other cancers1. There are two types of 
esophageal cancers: esophageal squamous cell cancer (ESCC) and esophageal adenocarcinoma 
(EAC). It is estimated that in 2017, 16,940 people in the US will be diagnosed with esophageal 
cancer and greater than 90% of those diagnosed will succumb to the disease1. There have been 
advances in surgical techniques, chemotherapy, and radiotherapy; however, these methods have 
not significantly modified patient prognosis over the past decades3–9. Diagnosis of EAC 
primarily occurs when it is at an advanced stage, resulting in an overall poor 5-year survival rate 
of less than 15%10.  ESCC main risk factors are smoking11, alcohol12, and socioeconomic 
factors13,14. Due to large efforts in reducing the smoking incidence, ESCC incidence has 
significantly decreased over the past decades and continues to decrease15. On the contrary, EAC 




(GERD), obesity, Caucasian race, and age over 4016. Obesity is becoming a global epidemic, and 
obesity is associated with the rise in GERD17, and EAC18–22. Although the incidence of EAC is 
increasing among most developed countries18,23, there is a significant difference in this incidence 
by race1,22,24, with African Americans having a low incidence of this type of cancer1,22,25,26.  
Many patients with EAC have associated with it Barrett’s esophagus (BE), a predisposing 
condition where the normal squamous of the esophagus is replaced by an intestinal-type 
columnar tissue27. Only about 1% of patients with BE will develop EAC28. The prevalence of BE 
is also significantly different between racial populations, with African Americans and Hispanics 
having a significantly lower frequency of BE when compared to Caucasians29–32. Interestingly, 
when looking at the common risk factors associated with development of EAC, such as obesity 
and GERD, there are no significant differences between Caucasians and African Americans29–32. 
The reasons for the high incidence of EAC in the Caucasian population vs. African Americans 
are currently unknown.  
 Understanding the progression of Barrett’s metaplasia to EAC and discovery of 
biomarkers that could stratify these patients based on the potential risk for developing EAC 
could potentially have a high impact on patient survival. In this introduction, we focus on the 
epidemiology, clinical features and molecular mechanisms that have been discovered for new 
diagnosis and therapeutic approaches for BE and EAC. We also discuss potential new methods 
to explore and risk stratify patients based on their potential to develop EAC from Barrett’s 
metaplasia.  
 
Esophageal Adenocarcinomas  




The metaplastic epithelium called Barrett’s esophagus (BE) was first described by 
Norman Barrett where he showed the apparent replacement of the normal squamous epithelium 
of the esophagus with a columnar mucosa that resembles intestinal epithelium33,34. He initially 
thought this was a congenital condition but it was later shown that it was acquired. GERD was 
later shown to be associated with Barrett’s development35 and in 1975 a study of 140 cases 
showed that 8.5% of those patients with BE developed EAC36. Only about 10-15% of patients 
with chronic GERD developed BE, this suggests that further genetic and environmental factors 
are possibly involved in the development of BE and/or EAC37.  
The process of neoplastic transformation from BE to EAC is thought to be a stepwise 
process, which involves a transition to low-grade dysplasia (LGD) to high-grade dysplasia 
(HGD) and finally to EAC (Figure 1.1). BE is considered an acquired premalignant lesion of the 
esophagus, although the exact mechanisms underlying its development and progression are still 
not understood. Some studies have shown that bile acids can cause injury in the esophageal 
squamous lining and lead to the development of metaplasia by inducing oxidative stress and 
DNA damage38,39. In addition, patients with central obesity are more predisposed to suffer from 
increased intra-gastric pressure, which increases gastroesophageal reflux disease (GERD), and 
subsequent are at higher risk for EAC40,41. Nevertheless, up to 40% of patients report no history 
of chronic GERD and develop EAC42. Studies trying to understand the progression from BE to 
EAC using expression profiles compared to normal tissue, have suggested different pathways 
activated in BE, but the cell of origin of BE remains known43. Patients who suffer from BE are 
enrolled in surveillance programs where they undergo biopsies of the BE by endoscopy to detect 
dysplasia by histopathology44–48. The process includes identification of either non-dysplastic 




however, some patients with BE under endoscopic surveillance often develop cancer without 
prior biopsy-based detection of any of these previously mentioned premalignant tissues (Figure 
1.3).  
GEJAC vs. EAC.  
 
The appropriate distinction between adenocarcinomas of the esophagus and the stomach 
has long been debated50-51 (Figure 1.2).  The appropriate classification of these tumors that span 
the gastroesophageal junction (GEJ) remains ambiguous. Due to this uncertainty, most treatment 
options and therapeutic approaches have relied on the use of anatomy and histology to classify 
this tumor types50,52,53 (Figure 1.2). One important aspect for elucidating the differences between 
these tumor types will be to understand their molecular characteristics, which in turn, may help 
classify each tumor type. Our group and others have focused on the molecular characterization of 
gastric adenocarcinomas54, esophageal squamous cell cancer55, and esophageal 
adenocarcinomas55. The Tumor Cancer Genome Atlas (TCGA) network, performed 
comprehensive molecular analysis of esophageal cancers subtypes revealing strong molecular 
signatures that are unique to each type. For example, ESCC is characterized by frequent genomic 
amplifications of CCND1, SOX2 and TP6355. On the other hand, EAC is characterized by more 
ERBB2, VEGFA, GATA4, and GATA6 amplifications. At the molecular level, EAC resembles 
more of a genomic profile similar to gastric adenocarcinoma, more specifically, those with 
similar chromosomal instability55. The observation that gastric and EAC share characteristics at 
the molecular level, suggests that they could be considered a single disease entity for future 
treatment strategies. In addition, others and our laboratory and collaborators have worked on the 




fluorescently-labeled peptide-based imaging agents to enhance endoscopic detection of specific 
cell surface markers as a means to improve early stage EAC diagnosis61,62. 
 EAC arises from the precursor lesion, Barrett’s esophagus (BE). Patients diagnosed with 
BE are enrolled in surveillance programs, where they undergo routine biopsy of the BE tissue to 
identify dysplastic progression and help to determine appropriate treatment. One of the current 
problems is the observation that >30% of GEJAC tumors present with no history or evidence of 
BE63,64. Making this group of patients, unlikely to be enrolled in surveillance programs. 
Therefore, understanding whether BE-derived EAC and non BE-derived GEJAC are molecularly 
distinct, as well as identification of cell surface markers for GEJAC, will potentially enhance 
early diagnostic tools and potential treatment for this patient cohort.  
Comprehensive genomic analyses of esophageal cancers. 
At the molecular level, genomic instability has been shown to be a fundamental property 
of the progression of the BE to higher grades of dysplasia and cancer65–69. Whole genome 
analysis studies have shown that BE samples show low levels of chromosomal instability, which 
include events such as copy number gains, losses, and loss of heterozygosity (LOH)70. The 
extent of genetic abnormalities correlates with the degree of dysplasia with BE showing less than 
2% and increasing to greater than 30% in later dysplastic stages, and tumors having the highest 
percentage of genomic abnormalities. The most frequent genetic alterations are a loss of 
chromosome 9p, TP53 mutations, APC and RB mutation and loss and overexpression of cyclin 
D1, Bcl2, and Src71,69,72. For many years it was thought that, at the genomic level, esophageal 
adenocarcinoma progresses through a stepwise progression where loss of CDKN2A was first 
observed followed by inactivation of TP53 with further increases in genome instability and 




is observed later, with TP53 being an early event, even identified in benign tissue (histologically 
benign non-dysplastic BE tissue)73. The majority of the tumors showed a genome-doubling 
event, with more amplification events observed, instead of inactivation of tumor suppressors. 
These key findings suggest EAC does not always progress in the common linear progression 
once thought, and that careful characterization of the TP53 gene and genome doubling could 
function as a potential early detection strategy73.  
 Our group and others have extensively characterized EAC at the DNA level71,74–83,67,66. 
More in-depth, we have performed a comprehensive analysis of copy number gain and loss69, as 
well as examining the mutational profile68 of EAC. EAC is characterized as having high copy-
number gain and loss, with recurrent focal amplifications centered near known oncogenes such 
as ErbB2, EGFR, K-RAS and focal deletions centered near CDKN2A and FHIT. In addition, our 
group demonstrated that EAC presents with more multiple amplification events as compared to 
either gastric or colon adenocarcinomas69. In addition, when characterizing the mutational profile 
of EAC, our group described a specific mutational signature of EAC, where we observed a high 
prevalence of A>C transversions at AA dinucleotides68. The observation of these specific DNA 
alterations in EAC and not others cancers, suggests that they may be driven by the unique 
environment during EAC development, mainly driven by the chronic inflammation associated 
with GERD. These specific observations and the mutational landscape, suggest that EAC reflects 
the unique environment of both GERD and chronic inflammation associated with EAC that 
together increases the frequency of these DNA alterations. 
The molecular characterization of EAC using exome sequencing and whole genome 
sequencing has revealed that most frequent mutations occur in tumor suppressor genes68, such as 




and the significant genomic instability and heterogeneity in these tumors, explains the poor 
advances in treatments in this type of cancer. A recent study, by Secrier et al.67, identified 
specific subgroups of tumors that were enriched for different targetable potential. For example, 
they identified a BRCA-signature with prevalent defects in the homologous recombination 
pathway. In the breast cancer field, there has been a success in targeting tumors containing the 
BRCA mutated and homologous recombination pathway84, therefore, this suggests that similar 
approaches could be used in patients with EAC that have this BRCA signature. Secrier et al.67 
also identified a dominant T>G mutational pattern associated with a high mutational load and 
increased neoantigen burden. Finally, a third group had an increased prevalence of a C>A/T 
mutational pattern with evidence of an aging imprint. This subgroup was categorized by a 
dominant T>G mutational pattern, with highest mutational burden, and highest neoantigen load. 
Therefore, potential therapeutics for this group could include immunotherapies such as CTLA4-
targeting agents and/or PD-1\PD-L1 treatments. These sub-clusters provide insight into 
categorizing EAC patients based on their mutational signature (C/A/T dominant group, the DDR 
impaired group, and the highly mutagenic group) for specific selection of targeted or other 
therapies.  
Clinical features of BE and EAC. 
BE patients are most often middle-aged, Caucasian males with a history of chronic 
GERD, and associated with extensive heartburn and chest pain for a long period of time85. 
Diagnosis of GERD and BE can be difficult, first, because some patients do not complain, or 
only show some of the common symptoms of GERD and secondly, because when symptoms do 
appear, their severity may not correlate with severity of the disease. While there is no effective 




increases the risk of risk of developing EAC86.  GERD clinical characteristics are only present in 
21% of EAC patients23. Most patients present with advanced disease, whose symptoms could be 
assigned to the direct effects of the regional, local or distant complications of the tumor. Many 
patients with EAC arrive with complaints of dysphagia (74%) and odynophagia (17%) at the 
time of diagnosis. There is also often weight loss, and if the patient has lost more than 10% of 
body mass this is associated with poor prognosis. 
Surveillance and detection of neoplastic progression of BE. 
Predicting which patients with BE will develop EAC is very difficult. The current clinical 
practice for the detection of the possible presence of EAC is by screening patients with high-risk 
gastro-esophageal reflux disease through endoscopy screening of the metaplastic BE tissue and 
to characterize the degree of dysplasia in the biopsy samples27,87. Patients are enrolled, based on 
clinical risk factors, such as long term GERD, male gender, being obese and over the age of 40.  
The screening program involves undergoing endoscopic-biopsy every 3 months to 2 years 
depending on the degree of dysplasia, during which 4 quadrant biopsy samples are taken every 1 
to 2 cm and then evaluated for histologic changes by expert pathologists27,87. Dysplasia grading 
remains an important basis of surveillance for patients with Barrett’s esophagus and many 
studies have shown that this method is associated with detection of EAC at an earlier stage, and 
this, in turn, has helped the patient outcome. One of the flaws of this approach is the random 
sampling of the endoscopic biopsies. Our group has suggested a more targeted approach, and we 
have developed fluorescently-labeled peptides that can identify the cancer cells. Importantly, a 
recent study by our group and collaborators shows the potential for detection of EAC in vivo 
through the use of fluorescently-labeled peptides detected by endoscopy after administration into 




overexpressed in high-risk cells could facilitate the early detection of tumors located in the distal 
esophagus or gastric cardia.  
Risk factors for progression. 
Multiple studies have identified additional factors at the time of endoscopy that can 
inform for the potential risk of BE progression. There have been four studies that associated the 
presence and length of the hiatal hernia to progression19,85,88,89. A hiatal hernia is characterized as 
a portion of the upper stomach inserted through the diaphragmatic hiatus into the chest cavity.  
Avidan et al.85 and Weston et al.88 reported an association and prediction of progression that was 
correlated to the size of the hiatal hernia. In contrast, in two larger cohort prospective studies and 
a case-control study Sikkemma et al.90 and Pohl et al.19 respectively, found no association 
between hiatal hernia and progression to EAC. It is known that the presence of a hiatal hernia 
increases the incidence of acid reflux; therefore, it is often associated with BE and progression 
and this is likely due to increasing chronic reflux as consequence of the protrusion of the 
stomach into the chest cavity.  
The length of BE is an additional clinical characteristic that some studies have associated 
with an increased risk of progression. Six studies found a range of results in terms of association 
of the BE length to the likelihood of progression to EAC. Rudolph et al.91 and Bhat et al.92 found 
in two independent studies that the length of the BE was not significantly correlated with the risk 
of progression. In contrast, Weston et al., Wong et al. and Sikkemma et al. found a significant 
correlation of long segment BE with a higher degree of dysplasia. It is difficult to define a 
specific cut-off length of BE associated with progression to EAC, however, many of these 






The risk of progression to EAC from HGD varies across studies, mainly because of the 
inconsistency in the techniques used to manage the HGD, which include differences in 
surveillance protocols, endomucosal resection (EMR), and esophagectomy91,93,94. Nonetheless, 
most studies have shown that at the time of HGD removal, there is evidence of EAC arising 
within the HGD. In a study conducted by Dar et al. they found that around 57% of patients 
undergoing esophagectomy for pathologically-confirmed HGD, also had an invasive foci of 
EAC95. Studies have found that detection of HGD is associated with a high risk of progression 
yet this poses significant problems since 1) there is inter-observer variability in diagnosis of 
HGD, particularly in establishing the correct grade as either LGD or HGD, 2) sampling error, 
where the actual dysplastic tissue may be missed and 3) evidence that EAC can arise without 
prior detection of the BE-dysplasia sequence.  
There are some clues at the time of endoscopy that can identify the potential risk for 
progression, nevertheless, identification of potential molecular biomarkers that could precisely 
risk stratify patients with BE and categorize subgroups at risk for development to HGD/EAC 
could enable more rational tailoring of endoscopic surveillance. Currently, upper endoscopy is 
the most extensively used tool to visualize and biopsy the esophagus to establish the 
identification of BE and potential progression. Current surveillance of patient with BE could be 
potentially enhanced by the use of biomarkers. Understanding and identification of markers that 
could predict subsequent incomplete response and/or relapse in patients who have undergone 
endoscopic eradication treatments for BE could potentially also help in the appropriate 





When identification of dysplastic BE or EAC occurs, there are a couple of clinical 
approaches to treating this disease. Patients that are diagnosed with high-grade dysplasia and 
therefore are at high risk for the development of cancer, require more aggressive approach. Often 
esophagectomy is the prevailing method to treat cancer and HGD but is associated with a 
mortality and morbidity frequency of 3-5% and 20-50% respectively96. Another alternative 
approach is endoscopic mucosal resection (EMR), a procedure in which specific regions of the 
mucosal esophagus lining is resected with a definite histologic diagnosis performed and shown 
to be curative in some cases97. The caveat of this approach is that since it only targets some 
regions of the lesions, neoplastic recurrence can be observed in up to 20% of cases during 
follow-up98. Because acid reflux is known to play a significant role in the development of 
dysplasia, most treatment strategies also include acid-blocking drugs or anti-reflux surgical 
procedures. However, no prospective trials currently exist showing that regulation of reflux 
symptoms has an impact on the prevention of the development of EAC. There is reported of a 
50% reduction in the risk of development of EAC in patients taking non-steroidal anti-
inflammatory drugs (NSAID)99,100. BE neoplastic progression to EAC is a complex process, and 
this suggests inflammation is an important factor. Further elucidation of better strategies for 
reducing cancer risk in patients with BE is currently needed. Additionally, risk stratification is 
required to maximize surveillance strategies and therapeutic decisions.  
Conclusion 
Patients who have gastro-esophageal reflux disease (GERD) often develop Barrett’s 
metaplasia, but only a small subset of patients with BE progress to adenocarcinoma23,86. The use 
of endoscopic surveillance coupled with a histological assessment and other variables can be 




of the tissue can miss the tissue where the dysplastic and/or cancer cells are arising. The 
observation that a percentage of tumors in the cardia/GEJ arise without a previous existence of 
BE, poses another challenge to identify these patients. Therefore, the main goals of this thesis are 
to elucidate the molecular events that distinguish GEJAC vs EAC and to characterize, at the 
transcriptome levels, the events that associated with BE dysplastic progression to EAC. In 
addition, to identifying cell surface overexpressed biomarkers, for the detection of HGD, 
GEJAC, and EAC. Finally, we aimed at elucidating the genetics events that could be driving the 
significance difference in the incidence of EAC between Caucasians and African Americans. 
With the development of new detection techniques for early diagnosis and potential preventive 
treatments, we expect, in the future, to positively impact and increase the 5-year survival rate for 






















Figure 1.1 Graphical depiction of histology observed in the replacement of esophageal 
tissue with Barrett’s esophagus. Esophageal squamous mucosa in the presence of GERD gets 
replaced with intestinal type tissue (bottom panel), that contains globet cells (blue cells) and 
produce mucin (yellow dots), which function as a protective mechanism against constant acid 
reflux. The intestinal-type BE tissue may progress through low-grade dysplasia, and to high-
grade dysplasia (HGD) and is associated with loss of glandular BE structure and loss of mucin 
production. Finally, esophageal adenocarcinoma (EAC) is depicted when abnormal malignant 
cells have invaded through the basement cell membrane. (modified from Anaparthy and Sharma 





Figure 1.2 Siewert-Stein classification of the location of esophago-gastric junction (GEJ) 
tumors. Type I Adenocarcinoma of distal part of the esophagus (located within between 1-5cm 
above the anatomic GEJ) Type II Adenocarcinoma of the real cardia (within 1cm above and 
2cm below the GEJ) Type III Adenocarcinoma of the subcardial stomach (2-5cm below GEJ) 











Figure 1.3. Current methods for the diagnosis of malignant progression to esophageal 
adenocarcinomas (EAC) in patients with Barrett’s esophagus (BE). Patients that are 
diagnosed with BE are enrolled in an endoscopic surveillance program where biopsies of the BE 
tissue are taken and submitted for histopathological assessment of dysplasia grading. ND and 
LGD have a less risk of progression to EAC and patients are scheduled to receive surveillance 
every 3 years or 12 months, respectively for subsequent biopsy. Patients with HGD are at much 
higher risk of malignant progression, therefore, they should undergo endoscopy and biopsy every 
3 months, or receive treatment for removal of the HGD regions by surgical or ablation methods. 
(Some of the pictures and figures presented here were modified from Conteduca V et al.101 and 
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Genomic Similarities Between Gastroesophageal Junction and  





The current high mortality rate of only a <15% five-year survival for esophageal 
adenocarcinoma (EAC) reflects frequent presentation at an advanced stage. Recent efforts 
utilizing fluorescent peptides have identified overexpressed cell surface targets for endoscopic 
detection of early stage Barrett’s-derived EAC. Unfortunately, 30% of distal AC patients present 
with gastroesophageal junction adenocarcinomas (GEJAC) without premalignant Barrett’s 
metaplasia, thus limiting this early detection strategy. We compared mRNA profiles from 52 
EACs (tubular EAC; tEAC) collected above the gastroesophageal junction with 70 GEJACs, 8 
normal esophageal and 5 normal gastric mucosa samples. We also analyzed our previously 
published22 whole-exome sequencing data in a large cohort of these tumors. Principal component 
analysis, hierarchical clustering and survival-based analyses demonstrated that GEJAC and 
tEAC are highly similar, with only modest differences in expression and mutation profiles. The 
combined expression cohort allowed identification of 49 genes encoding cell surface targets 
overexpressed in both GEJAC and tEAC. We confirmed that three of these candidates (CDH11, 
ICAM1, and CLDN3) were overexpressed in tumors when compared to normal esophagus, 
normal gastric and non-dysplastic Barrett’s mucosa, and localized to the surface of tumor cells. 
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Molecular profiling of tEAC and GEJAC tumors indicated extensive similarity and related 
molecular processes. Identified genes that encode cell surface proteins overexpressed in both 
Barrett’s-derived EAC and those that arise in GEJAC without Barrett’s metaplasia may allow 
detection of both types of cancer.  
Introduction 
 Over the past three decades, the incidence of GEJAC and EAC in the US has risen at a 
rate of 7.5% per year2, with other Western countries reporting similar increases3-4. Currently this 
disease presents within a characteristic demographic, such that approximately 80% of new cases 
arise within Caucasian males over the age of 40 years5-6, and while the reasons for the rapid 
incidence increase are undetermined, it is clear that obesity, smoking and particularly chronic 
GERD each play an important role. Advances in diagnostic and treatment approaches have 
improved short-term treatment responses, yet only one in five patients survive 5 years post-
diagnosis7. The greatest obstacles for improving patient survival include an advanced stage at 
diagnosis and an incomplete response to chemoradiotherapy8–10. Evidence from several small-
scale programs suggests an early diagnosis via adequate surveillance can dramatically improve 
EAC patient survival11-12, as well as reduce the need for aggressive chemoradiation8. Therefore, 
there is a pressing need to implement efficient, accurate surveillance programs among high-risk 
populations.  
We13 and others14-15 are developing fluorescently-labeled peptide-based imaging agents 
to enhance endoscopic detection of specific cell surface markers as a means to improve early 
stage EAC diagnosis. EAC arises from the precursor lesion, BE, which becomes dysplastic in a 
small minority of cases16. The presence of BE is currently the key factor for enrollment in 




trigger for treatment interventions, including surgical or endoscopic mucosal resection (EMR) of 
HGD. However, 25-30% of EAC cases present with no histological evidence or history of 
BE17,18. Adenocarcinoma of the distal esophagus and junctional cardia do share many 
characteristics (reviewed by Carr et al.19) and are currently treated using similar surgical and 
chemotherapy treatment strategies. At the University of Michigan Hospital, 30% of EACs arise 
at the GEJ that are not associated with the presence of BE9. Others have reported similar findings 
suggesting that GEJAC tumors make up a high proportion of EAC cases with no history of BE17. 
Here we applied molecular profiling technologies to assess the relationship between GEJAC and 
EAC, and expression profiling as an initial screen to identify potential cell surface markers for 
the detection of both GEJAC and EAC regardless of the prior presence of Barrett’s mucosa.  
Results 
GEJAC and tEAC Demographics  
Table 2.1 summarizes the key characteristics of the 122 EAC tissues used for expression 
array analysis. There were no differences associated with gender, BMI, stage, node status, 
adjuvant treatment or tobacco usage between GEJAC and tEAC (Table 2.1), yet GEJAC cases 
presented at a slightly older mean age. We saw minimal differences in semi-quantitative 
measures for tumor histological characteristics, including desmoplastic response, differentiation 
or the degree of lymphocytic invasion within each tumor.  
We used detailed pathology records to assess the presence or absence of BE. We found 
that 77% (54/70) of GEJACs arose in the absence of BE, significantly more frequent (p=3.13e-
05) than among tEAC samples (46%; 24/52). Given the strength of this result, the consistency 
with previous studies8, 10, 17, 20, and difficulties associated with clear demarcations on the basis of 




evidence of underlying BE (perhaps representing GEJAC arising from cardia) to the 28 EACs 
with histologically confirmed BE. As shown in Table 2.1, when comparing these more rigorous 
subsets there were no differences in clinical characteristics. We also compared GEJAC with and 
without BE, and tEAC with and without BE across clinical parameters and found that for both 
tumor subsets the presence of BE was associated with a higher frequency of early stage tumors, 
as has been published previously21. Note that with only 11 cases of GEJAC with evidence of BE, 
therefore the GEJAC comparison is underpowered (Table 2.2).  
Mutation Comparisons of GEJAC and tEAC  
Using whole-exome sequencing data from 149 normal and tumor pairs, those samples 
with available pathology information assigning tumors as either tEAC (n=53) or GEJAC (n=41) 
in the original paper were chosen22. Figure 2.1A shows no significant differences in the total 
number of non-silent, protein-coding mutations between GEJAC and tEAC tumor groups, while 
Figure 2.1B shows that GEJAC mutations are significantly (p=0.02 Wilcoxon Rank-sum test) 
less likely to involve the ApA dinucleotide, a signature mutation associated with EAC22-23. 
Although the incidence of all mutations shown in Figure 2.1 were previously described by 
Dulak and coworkers22, specifically comparing the incidence of mutations between GEJAC and 
tEAC was not presented in that study. Here we show that profiles of certain mutations (identified 
by Dulak) only slightly differ between GEJAC and tEACs. Among the 26 significantly mutated 
genes we found no difference in the overall mutation frequency (Figure 2.1C; p=0.13 Wilcoxon 
Rank-sum test) between GEJAC and tEAC, though the mutation profile was significantly 
different (p=0.047 by paired T-test; Figure 2.1D). While the most mutated gene in EAC by 
WES, TP5322-23, had a similar mutation frequency in both GEJAC and tEAC (75 and 77% 




higher mutation rate in tEAC (AKAP6, TLL1, AJAP1, ACTL7B, F5 and CNTNAP5) relative to 
GEJAC (Figure 2.1D), but the per gene mutation counts (ranging from 1 to 9 in either GEJAC 
or tEAC groups) were too small for individual gene statistical comparisons. Of the top 26 genes, 
only MYST3 showed a notably higher mutation rate in GEJAC (9.8%; 4/41) compared to tEAC 
(<2%; 1/53).  
We then considered GEJACs without BE vs tEACs with BE and saw the above results 
recapitulated, with a significantly lower fraction of ApA mutations in GEJAC without BE 
(p=0.023 by Wilcoxon Rank-sum test) and a significant difference in the distribution of 
mutations across the same 26 genes (p=0.04 by paired T-test), as well as similar individual gene 
profiles to those of the parent dataset listed above (Figure 2.2).  
Unsupervised Clustering of 122 Tumors  
We used PCA and unsupervised hierarchical clustering to investigate whether GEJAC 
represents a distinct, overlapping or indistinguishable subset of EAC, based on whole-genome 
expression profiling. For PCA we used all 26,613 annotated array elements across 135 mRNA 
samples (NE=8, NG=5, GEJAC=70, tEAC=52) and found that both types of normal samples 
were clearly separated from the tumors within the first 3 principal components (PC) (Figure 
2.3). To improve resolution within the cancer group we repeated PCA using only the 122 tumor 
samples (Figure 2.4). We then overlaid tumor location information, either GEJ or tubular 
esophagus, (Figure 2.4A), and assessed membership across PC1 and PC2, which each accounted 
for >5% of the total variance (Figure 2.5). We performed unsupervised hierarchical clustering 
by Pearson correlation and complete linkage across all 135 mRNA profiles that resulted in 4 
basic clusters; NE and NG groups, as well as two cancer clusters, designated C1 and C2 in 




considered the same two PCs in order to provide a point of comparison (Figure 2.4B). We used 
the Wilcoxon rank sum test to assess whether there was a difference in sample distribution when 
location (Figure 2.4A) or unsupervised hierarchical clustering (Figure 2.4B) were used to group 
tumors. While the GEJAC and tEAC comparison did give a significant different across the first 
PC (p=0.044) we saw no obvious subgroups or division of samples. By contrast, and as expected, 
the difference resulting from the unsupervised hierarchical clustering of tumor samples by gene 
expression was visibly and significantly separated (p=7.1E-16), although still overlapping 
(Figure 2.4B). The results were very similar when only GEJAC without evidence of BE were 
compared to tEAC with BE using the same procedure outlined above (Figure 2.7), 
demonstrating that the presence or absence of BE was not a key determinant.  
GEJAC and tEAC Expression  
Comparing the expression profiles of GEJAC and tEAC directly resulted in 1,368 
differential probesets (ANOVA p-value < 0.01), although only 96 (7%) had a fold-change (FC) 
difference >1.5. Given the low number of transcripts with meaningful FC shifts in this 
comparison, gene ontology analysis was conducted on all 1,368 using DAVID (1,183 unique 
Entrez gene IDs). This identified two over-represented gene categories (hsa05322: Systemic 
lupus erythematosus and hsa04514: Cell adhesion molecules), however, only one gene, HLA-
DRB3, (one of four genes common to both ontology categories) had >1.5-fold difference 
between GEJAC and tEAC.  
As a more sensitive comparison, we identified genes that distinguished GEJAC and tEAC 
from normal (NG plus NE) tissue (ANOVA<0.01 and FC>1.5), then considered either increased 
(FC>1.5) or decreased (FC<0.67) in the cancer groups relative to normal tissues. As expected, 




compared with normal tissues for both cancer groups, including cell cycle, immune response, 
extra cellular matrix structural factors, cell adhesion and digestion related categories; all 
previously reported in association with EAC. To compare the relative strengths of these ontology 
categories, we plotted the –log base 10 of Benjamini adjusted p values for ontologies over-
represented within GEJAC against the corresponding values resulting in tEAC (Figure 2.4C). 
We considered >105-fold difference between these matched p values (dotted lines marked on 
Figure 2.4C) to indicate a particular ontology category was more strongly represented within 
one cancer group. We assessed biologically relevant gene categories (relative to normal tissues) 
that might be more or less represented in GEJAC or tEAC. The majority of biological processes 
perturbed in EAC were similarly well represented in GEJAC and tEAC (Figure 2.4C), however, 
cell cycle and inflammation-related categories were more strongly represented in tEAC relative 
to GEJAC. 
Transcripts Associated with Overall Survival  
By applying univariate COX analyses, we identified 1,289 Entrez genes (1,462 
transcripts, including unknowns) with log-rank test p values <0.05 to overall survival in our 
treatment naïve cohort of 116 EACs from patients surviving more than 3 months post-surgery. 
This was very similar to the 1,331 transcripts (5% of 26,613) expected by chance. Of these just 
over half, 689 genes (784 transcripts), showed increased expression with increased risk (relative 
risk >1), which were overrepresented with members of the cadherin gene family residing in 
chromosomal band 5q31, in addition to a broad group of transcription-related genes. The 
contrasting set of 601 genes (679 transcripts), where reduced expression was associated with 
decreased overall survival, were over-represented by structural mitochondrial genes including a 




While no individual genes passed the false discovery adjusted significance threshold of 
0.05, one gene, ZNF217 had an FDR adjusted p=0.054 and a 2.3 hazard ratio (95% confidence 
interval of 1.6 to 3.3). The next strongest scores were for a cluster of 12 loci with FDR adjusted p 
values ranging from 0.29-0.3. These genes were associated with modest relative risk 
contributions of less than 2.5-fold with the majority showing increased expression and increased 
risk. Among these 13 genes, the highest risk ratio was 5, for the pseudogene GTF2IP1, and the 
lowest was 0.4 to PIGW. Of interest were several zinc finger factors (ZNF217, ZNF117, 
GTF2IP1 and MEX3D), though sparse in silico evidence links these genes.  
As the gene with the strongest correlation to survival in our cohort, we used Kaplan-
Meijer plots to compare samples with high and low ZNF217 expression for all 116 EACs, as 
well as GEJAC (n=67) and tEAC (n=49) subsets. We also assessed potential dependences on key 
clinical features using multivariate COX regression analysis (Figure 2.8A–C). We used median 
expression across each tumor cohort to dichotomize high and low mRNA expression and 
reported log-rank p-value comparisons for each of these groups. These data confirmed a 
consistent, but modest survival benefit to EAC patients with low ZNF217 expressing tumors 
(p=0.0034), with the same trend present in both GEJAC (p=0.0039) and tEAC (p=0.065) subsets.  
We identified histological stage, node positivity, smoking history and tumor location as 
clinical variables with a univariate association with survival (Figure 2.8D). In the univariate 
analyses of tumor location (GEJAC vs tEAC) we saw that GEJAC was associated with a slight 
but significant improvement in overall survival by log-rank statistic (p=0.0044; Figure 2.8D). As 
can be seen in Table 2.1 and Table 2.2, in our cohort there was a non-significant trend for 
GEJACs to present at an earlier stage, such that 40% of GEJACs presented with early stage 




GEJAC (AEG II) showed a shift towards earlier stage at presentation, however, Clark et al.17 and 
Curtis et al.20 did not. When we restricted our comparison to early stage GEJAC vs early stage 
tEAC (Figure 2.9B), or compare the late stage subsets (Figure 2.9C), this relationship to overall 
survival disappeared (p=0.109 and p=0.169 respectively). We are unsure why, in our cohort, 
more GEJAC patients have an earlier presentation, however, given the strong correlation of 
disease stage to overall survival (Figure 2.8D) this difference in the distribution of disease stage 
may explain the improved survival for GEJAC patients. Multivariate analysis demonstrated that 
ZNF217 over expression was independent of tumor stage, with other clinical variables having no 
significant impact on the model, including location (Figure 2.8D).  
Cell Surface Markers for GEJAC and EAC  
We used a three-step procedure (Figure 2.10) to identify overexpressed cell surface 
markers potentially useful for endoscope-based13 detection of both GEJAC and tEAC. Firstly, 
differential genes distinguishing GEJAC (n=70) from NE and NG expression profiles were 
identified using both ANOVA (p<0.01) and fold-change (>2) thresholds, represented as Venn 
diagrams in Figure 2.10: Step 1. This resulted in 396 transcripts for GEJAC and 534 when the 
same criteria were applied to tEAC (n=52) of which 359 were common to both lists (91% of the 
smaller list: Figure 2.10: Step 2). We also used 2-fold rather than 1.5-fold to improve the 
prospect of qRT-PCR validation. Combined, the two lists totaled 571 transcripts, corresponding 
to 523 Entrez gene IDs. The broad gene ontology category GO:0005887 was used to identify 
plasma membrane associated factors within our list of genes overexpressed in GEJAC and/or 
tEAC and found 253 of the 523 encoded cell membrane proteins (Figure 2.10: Step 3).  
As a final step, we examined our prior BE-EAC progression cohort (GEO series 




(LGD) (n=15), high-grade dysplasia (HGD) (n=7) and EAC (n=15). We identified 684 
transcripts overexpressed in EACs compared to BE without dysplasia, which included 151 genes, 
represented in GO:0005887 (Figure 2.10). We then compared this list of genes overexpressed in 
EAC relative to BE to the list generated above and overexpressed in EAC (GEJAC and tEAC) 
relative to normal tissues. We found 49 membrane-associated genes that overlapped. Heat maps 
of these 49 genes for GEJAC vs normal tissues, tEAC vs normal tissues and the GSE37203 
progression series (Figure 2.11A, Figure 2.11B, and Figure 2.11C respectively) demonstrated 
that while expression was collectively higher in each tumor set, relative to non-cancer tissues, 
each individual gene was high in only a subset of tumors. The 3 genes that passed selection 
thresholds for GEJAC, but not tEAC, (top genes in Figure 2.11A, 2.11B, and 2.11C) were also 
overexpressed in a number of tEACs. Similarly, the last 9 genes listed in each Figure 2.11 panel 
passed our expression threshold in tEAC only but were overexpressed in a similar portion of 
GEJACs. Thus the GEJAC and tEAC group-specific expression trends were very similar across 
the 49 genes.  
While the mean expression for each tumor group represented in each Figure 2.11 panel 
was higher than the non-cancer sample groups for each of the 49 genes, each gene had a number 
of individual cancer samples with expression levels comparable to normal tissues. This lower 
expressing subset varied for each gene thus to discriminate the majority of EACs from 
surrounding tissues, multiple genes are required. While some degree of correlated expression 
was evident among the 49 genes, several had more unique expression profiles, including CLDN3 
and SLC19A3, potentially representing valuable additions to a detection panel.  
Seventeen of the 49 potential cell surface marker genes identified were previously 




EAC expression, relative to BE, in multiple studies. In addition, we recently showed TGM2 is 
overexpressed on the surface of EAC cells26. In the current study, we chose to validate CDH11, 
ICAM1, and CLDN3 as examples of potential cell surface markers common to subsets of both 
GEJAC and tEAC.  
Using an expanded cohort including available arrayed samples (7 NE, 5 NG, 58 GEJAC, 
46 EAC) together with additional samples (1 NE, 1 NG, 7 BE, 19 LGD and 29 HGD), qRT-PCR 
was used to confirm overexpression of selected candidate genes in cancer relative to normal and 
precancerous tissues (Figure 2.12). Figure 2.13 demonstrates that Pearson-correlation analyses 
CDH11, ICAM1 and CLDN3 among Human Gene 2.1 ST arrayed samples indicate consistent 
correlations between log2 array and relative expression (qRT-PCR) data (rho values of 0.84, 0.81 
and 0.89 respectively). While each gene showed a clear difference between NE and either 
GEJAC or tEAC, differences were less distinct among non-cancer columnar tissues (NG and the 
BE groups: BE, LGD, HGD) (Figure 2.12A) suggesting that these genes would only be useful 
for distinguishing cancer foci from pre-cancer and normal tissues, rather than markers for 
identifying high-risk epithelium. Using our TMA with commercially available antibodies as 
shown in Figure 2.12B, cell surface expression of these markers was observed in HGD and 
EACs, although high-level expression was only observed in a small subset of tumors. For 14 
EACs we had matching mRNA and TMA data. Although this overlapping subset was small, 
there was a trend towards specimens with higher mRNA levels staining strongly for the 
corresponding protein (data not shown). While protein detection sensitivity may be an issue, 
there are many biological considerations that influence protein to message ratios, such that 






We found that GEJACs have significantly less histological evidence of BE when 
compared to tEAC, yet molecular comparisons of these tumor classifications using DNA 
mutation and mRNA expression profiling suggest only minor differences, even when the 
presence or absence of BE was taken as a co-discriminator. Minor differences were also 
observed in both mutation profiles, with less ApA mutations among GEJACs (a recognized 
characteristic of the EAC mutation profile22-23), and over-represented gene ontologies, with less 
cell cycle and immune response factors overexpressed in GEJAC. Together these observations 
may suggest that a subset of EACs arise as a result of a more extreme set of conditions requiring 
more prominent mucosal defense and an increasing the likelihood of initiating the formation of 
BE (with goblet cells), although resulting tumors arise via the same set of mutagenic triggers.  
Although pathology confirmed >70% viable tumor in each cancer specimen is it possible 
that associated normal tissue present may have masked GEJAC and tEAC cellular differences. In 
this case, microdissection rather than macrodisection may better discriminate GEJAC and tEAC. 
However, it should be noted that were true, then our mutation analysis would still have detected 
the differences between tumor cell types. We believe the subtle differences we observed by both 
expression and mutation analyses suggest that GEJAC and tEAC cancer cells are similar. As we 
move into IHC screening of our cell surface markers, we will be able to discern not only whether 
these proteins localize to the cell surface, but also which cells are staining. Markers that highlight 
stromal cells, rather than tumor cells will not be prioritized for validation as the relationship 
between stroma, activated stroma, and tumor cells is still an emerging field of investigation. 
Expression data revealed 1368 transcripts were significantly different between GEJAC and EAC, 




difference between tumor groups. As expected from these minor differences, PCA analysis 
showed that tumor location (GEJAC or tEAC) was not a strong influence on gene expression 
profiling.  
 These results are consistent with epidemiological studies that demonstrate most risk 
factors for GEJAC and tEAC are shared, with subtle patient differences in obesity-related 
factors, reflux, and gender (reviewed by 19, 27). A significantly reduced association between BE 
histology and adenocarcinomas arising at the GEJ has often been observed8–10,17,20, as we 
confirm here. The difference in BE rate does not translate into molecular differences suggests 
that the founding cell type(s), and pathway(s) for GEJAC and tEAC are shared. Molecular 
investigations of EAC indicate a heterogeneous disorder with different combinations of changes 
leading to cancer, suggesting the existence of molecular subtypes, as is the case for other 
common cancers. Unsupervised clustering of expression profiles in Figure 2.4 demonstrated that 
the underlying molecular characteristics were much stronger than minor differences attributed to 
GEJAC vs tEAC. Perhaps the underlying tumor causation spectrum is influenced by tumor 
location, though the specific investigation of this hypothesis is beyond the scope of the current 
study. When examining the DNA copy number variations of 27 GEJAC tumors, Isinger-Ekstrand 
et al. (28) also found that junctional AC profiles mirrored those of tEAC and were distinct from 
changes frequent in non-cardia gastric cancers. We report that both expression profiling and 
mutation analyses suggest a shared etiology for GEJAC and EAC of the distal esophagus. This 
holds true whether group distinction was based solely on tumor location, or whether the absence 
of BE was included as a co-discriminator. It should also be noted that a lack of evidence of BE at 
the time of surgery does not exclude the possibility that it was either missed (present in 




leaving no evidence at surgery.  
The known association of EAC with BE has led to surveillance biopsy protocols with the 
intent to detect early cancer in these patients. The reduced incidence of BE, however, suggests 
that a large proportion of individuals at risk for GEJAC are unlikely to be considered for routine 
screening. The development of novel fluorescently-labeled peptides for endoscopic identification 
of early cancer in the esophagus13 has increased the potential for the detection of early Barrett’s-
associated adenocarcinomas, with the promise of improving patient outcomes. The strong 
similarity between Barrett’s-associated EAC and GEJAC, as shown in the present study, 
suggests that potentially useful peptides could be developed that would identify cancers of both 
the lower esophagus and GEJ, regardless of the presence of Barrett’s esophagus.  
Univariate COX analysis for overall survival against all 26,613 annotated transcripts 
showed that over expression of ZNF217 mRNA represented the strongest gene-based risk within 
our cohort, with both GEJAC and tEAC samples showing support for this association (Figure 
2.8). While ZNF217 was the strongest, and just short of FDR-adjusted significance, several other 
genes show evidence of an association, though as with ZNF217, their relative risk contributions 
were small (<2.5 fold). In other cancer types, both mRNA and protein levels for ZNF217 have 
been shown to correlate with patient outcomes, including breast, ovarian, colon and prostate 
cancer types (recently showed by 29, and reviewed by 30, 31). These associations generally 
correlate with the presence of gain of chromosome 20q, a frequent event in EAC32–35. Both 
ZNF217 protein and mRNA tumor expression have been associated with 20q13 copy number for 
several tumor types36–38. Geppert et al.39 used FISH to demonstrate that the presence of 
chromosomal gain involving ZNF217 predicted stage-independent survival in 130 EAC patients. 




Several lines of evidence implicate ZNF217 as a key player in the regulation of the 
epithelial to mesenchymal transition (EMT), including the discovery of CDH1 as a direct 
repression target40 and that ZNF217 expression can be directly regulated by several EMT-related 
miRNAs, including miR-2441, miR-20342 and miR200c43. In prostate cancer miR-203 exists in a 
double negative feedback loop with the EMT transcription factor SNAI2, along with ZNF21744 
and miR-203 was previously shown to differentiate EAC from BE and decreased expression 
associated with poorer EAC patient outcome45-46.  
Using ChIP-seq analysis Frietze et al.47 showed that ZNF217 associates with the 
repressive histone mark H3K27ac and H3K4me1. Transgenic models with up regulation of 
ZNF217 expression stimulate mesenchymal transition through the activation of Snail1 and 
Twist29. Thus epigenetic remodeling, with ZNF217 as a key component, could be a central 
feature in explaining the dynamic nature of EMT48.  
Our expression profiling analysis has revealed 49 genes encoding potential cell surface 
markers that demonstrate transcriptional overexpression in EAC tumors compared to normal and 
pre-cancerous tissue. We confirmed tumor-specific overexpression for three genes (CDH11, 
ICAM1, and CLDN3) using qRT-PCR, and demonstrated protein localization specific to the cell 
surface of tumor cells by IHC. In addition, we have recently demonstrated that TGM2 was also 
overexpressed and present on the cell surface of EAC cells26, while both PTGS2 (COX2) and 
TNFRSF12A are known to increase during the transition from BE to EAC49, 50. The products of 
several genes from our potential cell surface list are suspected of playing key roles in more 
general cancer-related activities such as immunosuppression/evasion (CD14 and CD86), cell 
migration (ICAM, CDH11) and proliferation (TGFB1, PMEPA1, PDGFRL, SLC19A3). Other 




squamous cell staining at the leading edge of the epithelial surface while SLC2A3 (GLUT3) 
expression is known be elevated in the tissue of smokers51. These factors, along with protein 
expression gradient, and overexpression frequency will need to be considered in the construction 
of a specific panel of markers to aid in the identification of early cancers. Ultimately we aim to 
apply a multiplexed panel of peptides using multispectral scanning fiber endoscope technology52 
to improve the success of histology-based screening programs for early EAC detection.  
Materials and Methods 
 Sample cohort.  
All samples were obtained following written, informed patient consent according to the 
approval and guidelines of the University of Michigan institutional review board. Tissues were 
obtained from patients undergoing esophagectomy for adenocarcinoma within the University of 
Michigan Health System between 1991 and 2012, without preoperative radiation or 
chemotherapy.  
A portion of each specimen was immediately frozen in liquid nitrogen and stored at 
−80°C until use. All resected cancers underwent pathological analysis, and only those indicating 
adenocarcinomas arising either within 1 cm above and 2 cm below the GEJ (Siewert type II10) or 
within the distal (tubular) esophagus, more than 1 cm above the GEJ (tEAC), were included in 
this study. A board-certified pathologist (DGT) performed categorical or semi-quantitative 
histopathological assessment of the sections as follows; tissue type (squamous, BE, cardia, 
gastric), tumor type (AC), differentiation (well, moderate, poor), desmoplastic response (weak, 
moderate, high) and inflammatory response (weak, moderate, high). We noted histological 
evidence of signet ring cells in seven tumors (4 GEJAC and 3 tEAC). Cryostat sectioning was 




and weight data, at the time of surgery, were extracted from patient records and used to 
determine BMI category as follows: ‘underweight’ (BMI < 18.5), ‘normal’ (BMI 18.5 to 24.9), 
‘overweight’ (BMI 25 to 29.9) and ‘obese’ (BMI 30.0 and above). Adjuvant treatment was 
considered positive when a standard chemo and/or radio treatment commenced within not more 
than three months after primary resection. Pathology reports were also reviewed regarding the 
presence of BE. A sample was considered positive for BE when the pathologist noted goblet 
cells among the columnar tissue at the margin of tumor sections, or when BE was noted in the 
resected material. Using this information, we have included additional analyses based on 
comparing the subset of GEJACs with no evidence of BE to the subset of tEACs where the 
presence of BE was noted as described below.  
 Whole exome sequencing comparison of GEJAC and tEAC.  
WES data generated by Dulak et al. (22) was used to investigate differential mutation 
profiling within GEJAC and tEAC subgroups with variant calling, annotation and sample 
characteristics provided in the original publication. We compared all non-silent mutations 
observed in GEJAC (n=41) or tEAC (n=52) samples using the Wilcoxon Rank- sum test, as well 
as a paired Student T-test (two-sided) comparisons of the non-silent mutations within the 26 
genes significantly mutated within the entire WES cohort (n=149) as originally identified22 using 
the MutSig algorithm53. We also conducted analyses in which we compared the subset of 
GEJAC samples where histology did not note BE (n=35; 85% of the GEJAC mutation cohort) to 
the subset of tEAC samples where BE was noted (n=42; 81% of the tEAC mutation cohort).  
 mRNA profiling. 
Total RNA was purified from normal esophageal squamous (NE; n=8), normal gastric 




(GEJAC; n=70), and within the ‘tubular’ esophagus (tEAC; n=52) using miRNeasy spin columns 
(Qiagen, Valencia, CA), including on-column DNAse I incubation, according to the 
manufacturer’s instructions. RNA samples with RIN scores greater than 6.0 (Bioanalyzer; 
Agilent Technologies, Palo Alto, CA), were submitted to the University of Michigan Cancer 
Center Genomics Core for cDNA synthesis, cRNA amplification (Ambion WT Expression Kit; 
Life Technologies, Grand Island, NY) and hybridization to Human Gene ST 2.1 arrays 
(Affymetrix, Santa Clara, CA) according to the manufacturer instructions. Expression values for 
each gene were estimated using the robust multi-array average (RMA) method54 in the 
Bioconductor package55 and log2-transformed. Analyses were restricted to the 26,613 coding 
and non-coding genes for which annotation details were available, including HUGO Gene 
Nomenclature Committee (HGNC) approved gene symbol and Entrez Gene ID.  
 Principal component analysis and unsupervised clustering.  
We used Cluster (version 3.0) to perform Principal Component Analysis (PCA) of 
expression array data to visualize the relationship between sample groups. Mean normalized, 
batch adjusted log 2 expression data for 26,613 annotated array elements were applied to PCA, 
either using all 135 samples (8 NE, 5 NG, 70 GEJAC and 52 tEACs) or just the 122 tumor 
samples. To generate two-dimensional plots, we compared the top principal components (PC), 
ranked by eigenvalues, which individually explained the highest levels of the total variance, 
using 5% as a minimum threshold for investigation. Among these components, those that best 
demonstrated the separation between sample groups were graphed. Typically, this meant the top 
two PCs were compared.  
The software packages Cluster (version 3.0) and Treeview (Java version 3.0 (56)) were 




using Pearson correlation with average linkage using 26,613 annotated array elements. Data were 
normalized to tumor means for each gene to aid in dendrogram visualization. This analysis 
resulted in normal samples clustering together and tumors separating into two groups, with 
mixed GEJAC and tEAC membership in each of these clusters (Figure 2.6). Given that GEJAC 
and tEAC groups were not distinct by either PCA or hierarchical clustering, the Pearson 
correlation cluster membership was overlaid onto the PCA graphs, as a comparison to 
demonstrate how well the sample cohort could be separated. We used this as a comparison 
purely to more clearly demonstrate that PCA incompletely discriminated between GEJAC and 
tEAC.  
 Gene ontology analysis of expression array data.  
The arrays were run in two batches, the first batch holding 8 NE, 5 NG, and 35 GEJAC, 
while the second batch consisted of 52 tEAC and an additional 35 GEJAC. We adjusted for 
batch effects by adding probe-set specific constants to each value in the second batch such that 
the probe-set means for GEJAC’s in batch 2 agreed with those of batch 1. When fitting a one-
way analysis of variance (ANOVA) model with means for each of the four tissue types, we 
reduce the degrees of freedom in the mean- squared-error and F-tests by 1 to account for this 
batch adjustment. Mean group expression ratios (typically >1.5 or 2-fold increase/decrease), in 
combination with an ANOVA test of p<0.01, were used to select differentially expressed genes 
between groups. Enrichment testing for over-represented gene ontology terms was performed 
using the DAVID website with the appropriate platform- specific background gene list (“HuEx-
1_0-st-v2”) and default algorithm settings57-58. Individual ontology categories with false 
discovery adjusted (Benjamini) p values <0.05 were reported, though we applied the modular 




assess redundant gene categories and to group similar gene sets under appropriate descriptors 
(59). Both batch- normalized and raw expression data for this experiment were deposited into the 
Gene Expression Omnibus (GEO series GSE74553).  
 Identification of genes associated with overall survival.  
Of the 122 tumors used in this study, there were 2 patients who died from surgical 
complications within a month of surgery, and a further 4 patients who died within 3 months of 
surgery (3 GEJAC and 3 tEACs combined). In order to reduce the possibility of surgical 
complications confounding survival data, we chose to use the identified 116 patients who 
survived more than 3 months following surgery. For these patients, the average survival time was 
38.7 months (range: 3 to 251 months), and an average follow-up time of 94.2 months (range: 18 
to 242 months) for surviving participants. Using univariate analyses, we determined that of the 
available clinical variables stage, node status, tumor location, and smoking status each showed 
an association to overall survival (Figure 2.8D). We applied univariate COX analysis for all 
26,613 annotated transcripts and applied FDR adjustment to the resulting log-rank (Mantel-Cox) 
test p-values. We considered genes with an FDR adjusted p value <0.05 to provide a significant 
association to overall survival. Survival associations were plotted (Kaplan-Meijer) using 
dichotomized mRNA expression, with cohort median expression as a cutoff. Multivariate 
analyses were used to assess whether the survival associations for significant genes were 
independent of stage, node status, tumor location and smoking status.  
 Identification of GEJAC/tEAC expressing genes for cell surface proteins.  
 To identify cell surface-coding genes selectively overexpressed in both GEJAC and 
tEAC, we applied a three-step procedure schematically represented in Figure 2.10. In step 1, we 




(FC) >2 and that this also was true for comparisons of tEAC vs NE and tEAC vs NG. In step 2 
we selected the subset of genes indicated as being “plasma membrane” by Gene Ontology 
(GO:0005887), as listed within the COMPARTMENTS subcellular localization database, which 
resulted in 5 162 potentials among the 26,613 transcripts60. For step 3, we then analyzed the 
resulting list of genes in our previously published, independent data-set of 9 BE, 7 BE+LGD, 8 
LGD, 7 HGD, 15 EAC assayed on Affymetrix U133A arrays (GEO Series GSE37203) in order 
to compare cancer (EAC) and non-dysplastic pre-cancer (BE) expression levels by ANOVA and 
fold-change25.  
 qRT-PCR validation.  
cDNA synthesis was performed using the High-Performance RT-PCR Kit (Life 
Technologies, Grand Island, NY) according to the manufacturer’s instructions. Total RNA from 
58 GEJAC and 46 tumors from the ST 2.0 array, 53 BE (7 without dysplasia, 17 LGD and 29 
HGD), 6 NG and 8 NE samples were available for real-time (qRT- PCR) validation of the 
selected gene transcripts. qRT-PCR reactions primers were designed using Primer-BLAST61 
(CDH11: 5’-GCACGAGACCTATCATGCCA-3’, 3’-CTGTCTGTGCTTCCACCGAA-5’, 
ICAM1: 5’-GTA TGAACTGAGCAATGTGCAAG-3’, 3’-GTTCCACCCG TTCTGGAGTC-5’, 
CLDN3: 5’- TCGGCCAACACCA TTATCCG-3’, 3’-GTACTTCTTCTCGCGTGGGG-5’, 
ZNF217: 5’- CTCCGGGCCACTTTACACTT-3’, 3’-TCTCT TTTGTGCCATGCTGTT-5’) or 
previously published (GAPDH: 62). Annealing temperatures were determined and optimized 
using Cepheid SmartCycler (Cepheid, Sunnyvale, CA). Samples were run using the ABI 
PRISM® 7900HT Sequence Detection System according to the manufacturer’s instructions and 
analyzed using relative quantitation utilizing GAPDH as the reference gene. Technical validation 




matched log2 ST 2.1 array data for each validation gene (Figure 2.13). GAPDH was chosen 
because it was highly expressed (mean log2 expression of 7.57 across all samples) with a 
minimal mean difference between normal and tumor samples (1.03-fold for 13 normal vs 122 
tumor samples) within our ST 2.1 array data and is known to be an effective reference for 
esophageal samples63.  
 Immunohistochemistry and tissue microarray (TMA).  
 A TMA was constructed as described by Kononen et al (64) containing 122 cores 
derived from the resected tissue from 73 EAC patients, including 60 tEAC, 3 GEJAC, 22 BE, 9 
metastatic lymph nodes, and 14 normal tissues. Five µm sections were used for 
immunohistochemistry as previously described25. CDH11 (Cat# 32-1700, Life Technologies), 
ICAM1 (Cat# ab53013, Abcam, Cambridge, MA) and CLDN3 (Cat# 18-7340, Thermo 
Scientific, Pittsburgh, PA) monoclonal antibody were used at dilutions of 1:500, 1:250 and 
1:100, respectively, after microwave citric acid epitope retrieval for 20 minutes and lightly 
counterstaining with hematoxylin. Each sample was then scored 0-3 corresponding to absent, 















Figure 2.1: Mutation profiling comparison of GEJAC and tEAC. Whole exome sequencing 
data were downloaded for a cohort of 149 normal-tumor pairs, with mutation type and frequency 
determinations performed as in Dulak et al. 2013. When looking at A) the total number of non-
silent mutations in tEAC vs GEJAC we found no significance difference based on tumor type. 
There was a modest difference when B) only mutations with the ApA dinucleotide profile were 
considered with the Wilcoxon rank-sum test. When only the originally identified 26 significantly 
genes were considered there was C) no difference in the summated number per sample (p=0.134 
by Wilcoxon rank-sum test), however D) there was significance when the collective mutation 





Figure 2.2: Mutation profiling comparison of GEJAC without BE and tEAC with BE. 
Whole exome sequencing data for GEJAC samples without BE histology (GEJACnoBE: n=35) 
and tEAC samples where BE histology was noted (tEACwithBE: n=42) were extracted from a 
cohort of 149 normal-tumor pairs, with mutation type and frequency determinations performed 
as in Dulak et al. 2013. When looking at A) the total number of non-silent mutations in tEAC 
with BE vs GEJAC no BE we found no significance differences. There was a modest difference 
when B) only mutations with the ApA dinucleotide profile were considered with the Wilcoxon 
rank-sum test. When only the originally identified 26 significantly genes were considered there 
was C) no difference in the summated number per sample, however D) there was significance 
when the collective mutation profiles for these genes were compared between GEJAC no BE and 
tEAC with BE by paired T-test.  
Supplementary Figure S1: Mutation profiling comparison of GEJAC without BE and tEAC with BE. 
Whole exome sequencing data for GEJAC samples without BE histology (GEJACnoBE: n=35) and tEAC 
samples where BE histology was noted (tEACwithBE: n=42) were extracted from a cohort of 149 
normal-tumor pairs, with mutation type and frequency determinations performed as in Dulak et al. 
2013. When looking at A) the total number of non-silent mutations in tEACwithBE vs GEJACnoBE we 
found no significance differences. There was a modest difference when B) only mutations with the 
ApA dinucleotide profile were considered with the Wilcoxon rank-sum test. When only the originally 
identified 26 significantly genes were considered there was C) no difference in the summated number 
per samp e, however D) there was significance when the collective mutation profiles for these genes 
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Figure 2.3: PCA analysis in all 4 mRNA profiling groups. All annotated probe sets 
(n=26,613), were standardized by subtracting the all sample cohort mean and dividing by the SD. 
A) The first two and B) first and third principal components were plotted and individual samples 
were assigned to their four histological groupings to demonstrate clear separation of normal 
tissues (NE and NG) but no separation of tumor groups (GEJAC and tEAC).  
Supplementary Figure S2: PCA analysis in all 4 mRNA profiling groups. All annotated probe sets 
(n=26,613), were standardized by subtracting the all sample cohort mean and dividing by the SD. A) 
The first two and B) first and third principal components were plotted and individual samples were 
assigned to their four histological groupings to demonstrate clear separation of normal tissues (NE and 
NG) but no separation of tumor groups (GEJAC and tEAC). 
All 135 mRNA samples PC#1 vs PC#2 







Figure 2.4: mRNA profiling comparison of GEJAC and tEAC. All annotated probe sets 
(n=26 613), were standardized by subtracting the tumor cohort mean and dividing by the SD. 
The first two principal components (each with variance >5%: Figure 2.5) were plotted and 
individual samples were assigned either A) a location (GEJ or tubular esophagus) or B) an 
unsupervised clustering assignment based on Pearson-correlation on the same 26 613 probe sets 
(Figure 2.6) Visual and statistical comparison demonstrates minor expression differences 
between GEJAC and tEAC compared to class assignment by gene expression. C) Gene 
ontologies significantly over-represented (DAVID generated Benjamini adjusted p values <0.05) 
in GEJAC comparison to both the normal tissue groups were plotted against their tEAC 
equivalent using a – log 10 (p value) format. Dotted and continuous lines represent 105 fold and 
1:1 ratio markers respectively Results demonstrate that genes related to the cell cycle and broad 
inflammation ontology categories were more enriched in tEAC relative to normal tissues, 




Figure 2.5: The fraction of variance in each principle component. All annotated probe sets 
(n=26,613), were standardized by subtracting the all sample cohort mean and dividing by the SD. 
The percent of total variance attributed to each principle component were then plotted to show 























Figure 2.6: Hierarchical clustering in 122 tumor mRNA samples. Unsupervised clustering 
assignment of all 122 tumor samples based on Pearson-correlation and complete linkage on all 
26,613 probe sets.  
Figure 2.7: PCA comparison of GEJAC noBE and tEAC with BE. All annotated probe sets 
(n=26,613), were standardized by subtracting the tumor cohort mean and dividing by the SD. 
Only GEJACs with no histological evidence of BE (GEJAC no BE; n=54) and tEACs with BE 
(tEAC with BE; n=28) were considered. The first two principal components (each with variance 
>5%: (Figure 2.5) were plotted and individual samples were assigned either A) a location (GEJ 
or tubular esophagus) or B) an unsupervised clustering assignment based on Pearson-correlation 
on the same 26,613 probe sets (Figure 2.6) Visual and statistical comparison demonstrated minor 
expression differences between GEJAC no BE and tEAC with BE compared to class assignment 
by gene expression, as was seen when all GEJAC and tEAC samples were compared (Figure 
2.4).  




Unsupervised Pearson clustering 
using all 26,613 transcripts 
Supplementary Figure S4: Hierarchical clustering in 122 tumor mRNA samples. Unsupervised 
clustering assignment of all 122 tumor samples based on Pearson-correlation and complete linkage on 
























































A. Tumor PCA grouped by 
location noting BE status 
B. Tumor PCA grouped by 
Pearson defined clusters 
Supplementary Figure S5: PCA comparison of GEJACnoBE and tEACwithBE. All annotated 
probe sets (n=26,613), were standardized by subtracting the tumor cohort mean and dividing by the SD. 
Only GEJACs with no histological evidence of BE (GEJACnoBE; n=54) and tEACs with BE 
(tEACwithBE; n=28) were considered. The first two principal components (each with variance >5%: 
(Supplementary Figure S3) were plotted and individual samples were assigned either A) a location (GEJ 
or tubular esophagus) or B) an unsupervised clustering assignment based on Pearson-correlation on the 
same 26,613 probe sets (Suppleme tary Figure S4) Visual and statistical comparison demonstrated 
minor expression differences between GEJACnoBE and tEACwithBE compared to class assignme t by 





Figure 2.8: Univariate and multivariate analyses of ZNF217. Univariate Kaplan-Meijer 
estimates with patients survived more than 3 months post-surgery stratified into high or low risk 
on the basis of median log2 normalized ZNF217 expression. Plots demonstrate higher ZNF217 
expression as a risk factor whether A) all EACs, B) GEJAC only and C) tEAC only patients are 
considered. D) Shows tabulated comparisons of univariate and multivariate Cox proportional 








Figure 2.9: Survival analyses comparing GEJAC and tEAC. A) Univariate survival analysis 
shows GEJAC had improved survival over tEAC, however by looking at B) early and C) late 
stage tumors separately, as well as D) multivariate analysis, indicated this association is 
dependent upon tumor stage. Kaplan-Meijer plots and log-rank p=values were generated in 
Prism while tabulate univariate and multivariate analyses were made using the coxph module in 
R. 
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Supplementary Figure S6: Survival analyses comparing GEJAC and tEAC. A) Univariate survival 
analysis shows GEJAC had improved survival over tEAC, however by looking at B) early and C) l te 
stage tumors separately, as well as D) multiva iate analysis, indicated this association is dependent upon 
tumor stage. Kaplan-Meijer plots and log-rank p=values w re generated in Prism while tabulate 
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Figure 2.10: Schematic of the steps used to identify potential cell surface markers for 
GEJAC and tEAC using expression profiling data. Beginning with all 26,613 probe sets the 
schematic demonstrates the bioinformatic steps and associated gene numbers as we combine 
comparisons to each normal tissue group (NE and NG) to each of the tumor group (GEJAC and 
tEAC), selected the combined subset with known plasma membrane associations by GO and 
finally contrasted this list to those similarly overexpressed in EAC relative to BE in our 
previously published progression cohort (GEO ID: GSE37203). The resulting 49 genes represent 
potential cell surface factors overexpressed in EAC (both GEJAC and tEAC) relative to 
surrounding normal and pre-cancerous tissues.  
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Supplementary Figure S6: Schematic of the steps used to identify potential cell surface markers 
for GEJAC and tEAC using expression profiling data. Beginning with all 26,613 probe sets the 
schematic demonstrates the bioinformatic steps and associated gene numbers as we combine 
comparisons to each normal tissue group (NE and NG) to each of the tumor group (GEJAC and tEAC), 
selected the combined subset with known plasma membrane associations by GO and finally contrasted 
this list to those similarly upregulated in EAC relative to BE in our previously published progression 
cohort (GEO ID: GSE37203). The resulting 49 genes represent potential cell surface factors 





Figure 2.11: Heatmap of potential cell surface coding genes for GEJAC and tEAC. 
ANOVA and fold-change based comparisons, in conjunction with Gene Ontology data, were 
used to identify 49 genes potentially over-represented in GEJAC and tEAC, as outlined in 
Figure 2.10 and Methods. Mean normalized expression was then applied to these data to sort 
expression patterns across A) GEJAC and B) tEAC relative to mRNA from normal tissues, as 
well as C) EAC relative to BE samples ordered by histology, taken from Gene Expression 
Omnibus (GEO) Series ID GSE37203) (Silvers et al. 2010). In each figure plate the top three 
genes only passed the overexpression threshold in GEJAC, the lower nine only passed in tEAC, 
while the central listed genes were selected in both cancer types. While all genes are generally 
more highly expressed in tumor groups as compared to the represented non-cancerous tissues, 
there was considerable variation between tumor samples, with no clear pattern in relation to 





Figure 2.12: qRT-PCR and protein validation of potential cell surface markers. Three 
genes, CDH11, ICAM1 and CLDN3, were chosen to confirm mRNA overexpression in EAC 
tumors, and demonstrate tumor cell surface staining of gene products.  A) Relative qRT-PCR 
expression levels were determined for an esophagus-related panel of cDNA samples using the 
ABI PRISM® 7900HT technology and GAPDH as a reference gene, as described in Methods. 
GEJAC and tEAC groups were not significantly different for any gene (p=0.12, 0.65 and 0.17 by 
WMU). The combined cancers were compared to NE, NG, BE and HGD groups (grey no 
significant comparison, * p<0.05, ** p<0.01, *** p<0.001 by MWU) for each of the 3 genes. B) 
We then used a TMA containing histologically-confirmed EAC tissues to demonstrate that 
commercially available antibodies for A. CDH11, B. CLDN3, C. ICAM1 and D. no primary 





Figure 2.13: Validation of ST 2.1 array data by qRT-PCR. Pearson-correlation analyses for 
A) CDH11, B) ICAM1 and C) CLDN3 comparing log2 normalized Human Gene 2.1 ST arrayed 
samples and relative expression (qRT-PCR relative to GAPDH) data.  
Supplementary Figure S7: Validation of ST 2.1 array data by qRT-PCR. Pearson-correlation 
analyses for A) CDH11, B) ICAM1 and C) CLDN3 comparing log2 normalized Human Gene 2.1 ST 
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Table 2.1: Clinical Characteristics 
  
GEJAC and tEAC  GEJAC no BE and tEAC with BE 
  
GEJAC tEAC   
GEJAC      
no BE 












Age  median 70.3 68.1 0.266# 70 69.7 0.914# 
   under 70 26 (37.1%) 29 (55.8%)   20 (37.0%) 14 (50.0%) 
      over 70 44 (62.9%) 23 (44.2%) 0.0453^ 34 (63.0%) 14 (50.0%) 0.345^ 
Gender           
    male 54 (77.1%) 47 (90.4%)   40 (74.1%) 25 (89.3%) 
    female 16 (22.9%)   5 (9.6%) 0.088^ 14 (25.9%)    3 (10.7%) 0.152^ 
Tumor Stage           
      I   9 (12.9%)   4 (7.8%)     6 (11.1%)   3 (10.7%) 
      II 19 (27.1%) 10 (19.6%)   12 (22.2%)   8 (28.6%) 
      III 37 (52.9%) 30 (58.8%)   32 (59.3%) 14 (50.0%) 
      IV   5   (7.1%)   7 (13.7%) 0.11@   4   (7.4%)   3 (10.7%) 1.0@ 
Node status           
   negative 21 (30.0%)   8 (18.2%)   14 (25.9%)   7 (29.2%) 
   positive 49 (70.0%) 36 (81.8%) 0.189^ 40 (74.1%) 17 (70.8%) 0.787^ 
Differentiation           
   well 16 (22.9%)  4 (7.7%)   12 (22.2%)   3 (10.7%) 
   moderate 22 (31.4%) 19 (36.5%)   17 (31.5%)   9 (32.1%) 
   poor 32 (45.7%) 29 (55.8%) 0.066@ 25 (46.3%) 16 (57.1%) 0.229@ 
Desmoplasia           
   low  25 (35.7%) 14 (26.9%)   19 (35.2%)   7 (25.0%) 
   moderate 21 (30.0%) 17 (32.7%)   15 (27.8%) 11 (39.3%) 
   high 24 (34.3%) 21 (40.4%) 0.379@ 20 (37.0%) 10 (35.7%) 0.676@ 
Lymphocytic infiltration         
   low  24 (34.3%) 12 (23.1%)   19 (35.2%)  7 (25.0%) 
   moderate 28 (40.0%) 16 (30.8%)   20 (37.0%)  9 (32.1%) 
   high 18 (25.7%) 24 (46.2%) 0.039@ 15 (27.8%) 12 (42.9%) 0.197@ 
Tobacco usage           
   no 19 (28.8%) 16 (34.0%)   15 (29.4%) 10 (40.0%) 
   yes 47 (71.2%) 31 (66.0%) 0.68^ 36 (70.6%) 15 (60.0%) 0.438^ 
BE status           
   no BE 54 (77.1%) 24 (46.2%)   100% 
 
  
  + BE 11 (15.7%) 28 (53.8%) 3.13E-05^ 
 
100%   
  unknown   5   (7.1%)   0      (0%)         
#, t-test: ^, Fisher Exact Test: @, Mantel-Haenszel Chi-square test of association 




Table 2.2: Clinical characteristics of BE related subtypes for each cancer group 
  





with BE   
tEAC      no 
BE 











Age  median 70 72.3 0.695# 66.2 69.7 0.173# 




     over 70 34 (63.0%)   7 (63.6%) 1.00^   9 (37.5%) 
14 
(50.0%) 0.412^ 
Gender           
 




   female 14 (25.9%)   2 (18.2%) 0.718^   2  (8.3%) 
   3 
(10.7%) 1.00^ 
Weight category            
 
 under weight  BMI < 18.5   1  (2.0%)   0  (0.0%)     0  (0.0%) 
  1   
(4.0%) 
 
 normal weight 18.5 – 24.9 17 (34.0%)   4 (36.4%)     5 (26.3%) 
  6 
(24.0%) 
 




 obese               30.0 and over  14 (28.0%)   4 (36.4%) 0.722@   4 (21.1%) 
  6 
(24.0%) 0.906@ 
Tumor stage           
 
     I   6 (11.1%)   2 (18.2%)     1   (4.3%) 
  3 
(10.7%) 
 
     II 12 (22.2%)   6 (54.5%)     2   (8.7%) 
  8 
(28.6%) 
 




     IV   4   (7.4%)   0   (0.0%) 0.0398@   4 (17.4%) 
  3 
(10.7%) 0.0747@ 
Node status           
 
  negative 14 (25.9%)   5 (45.5%)     1   (5.0%) 
  7 
(29.2%) 
 
  positive 40 (74.1%)   6 (54.4%) 0.275^ 19 (95.0%) 
17 
(70.8%) 0.0544^ 
Differentiation           
 
  Well 12 (22.2%)   4 (36.4%)     1   (4.2%) 
  3 
(10.7%) 
 
  moderate 17 (31.5%)   3 (27.3%)   10 (41.7%) 
  9 
(32.1%) 
 
  Poor 26 (46.3%)   4 (36.4%) 0.371@ 13 (54.2%) 
16 
(57.1%) 0.841@ 
Desmoplasia           
 
  low  19 (35.2%)   5 (45.4%)     7 (29.2%) 
  7 
(25.0%) 
 







  High 20 (37.0%)   0   (0.0%) 0.0837@ 11 (45.8%) 
10 
(35.7%) 0.793@ 
Lymphocytic infiltration          
   low  19 (35.2%)   4 (36.4%)     5 (20.8%)  7 (25.0%) 
   moderate 20 (37.0%)   6 (54.6%)     7 (29.2%)  9 (32.1%) 
 
  High 15 (27.8%)   1   (9.1%) 0.437@ 12 (50.0%) 
12 
(42.9%) 0.187@ 
Adjuvant treatment          
 




  positive 12 (22.2%)   3 (27.3%) 0.706^  8 (33.3%) 
  7 
(25.0%) 0.757^ 
Tobacco usage           
 




  Yes 30 (70.6%) 31 (66.0%) 0.68^ 36 (70.6%) 
15 
(60.0%) 0.438^ 
BE status           
   no BE 100% 
 
  100% 
 
  




100%   
  unknown   0   (0.0%)   0  (0.0%)         
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Patients with gastroesophageal reflux disease (GERD) often develop a metaplastic 
condition called Barrett’s esophagus (BE), but only a small subset of patients with BE progress 
to esophageal adenocarcinoma (EAC). The process of neoplastic transformation from Barrett's 
esophagus (BE) to EAC is a stepwise process involving progression from non-dysplastic BE 
mucosa to low-grade dysplasia (LGD), to high-grade dysplasia (HGD) and eventually 
adenocarcinoma. Patients with HGD have a >40% chance of developing EAC, making the HGD 
lesion the gold standard in the field for identification of EAC risk. Current strategies to diagnose 
the presence of HGD and EAC are through random biopsy of the esophagus and histologic 
assessment of the tissue to identify the high-risk tissue. Caveats of this approach include the 
potential missing of these events due to random sampling. Therefore, there is a current need for 
the development of new prevention strategies in patients with premalignant Barrett’s metaplasia, 
better methods for early cancer detection, and refining new treatment modalities to improve 
patient survival. In this work, we sought to characterize the molecular events that are associated 
with the progression of BE to LGD, HGD, and EAC, and to identify biomarkers for 
immunohistochemistry as well as a cell surface over-expressed marker in the HGD/EAC tissue 
that may serve as candidates for peptide-based imaging. Using RNA-sequencing on a 




HGD à EAC) we have identified deregulation of the splicing pathway, down-regulation of 
mucin protection, and subsequent increase in the DNA damage response pathway (DDR). In 
addition, for early diagnosis purposes, we identify two cell surface coding genes, C3 and HLA-
DRB5, that are overexpressed in the HGD/EAC and cancer, when compared to non-dysplastic 
BE or normal gastric and esophagus. ROC curves show that the expression levels of these 
markers are significantly sensitive and specific to differentiate between non-dysplastic BE vs. 
HGD/EAC and between normal tissues (esophagus and gastric) vs. tumors (EAC/GEJAC).  
Introduction 
In the United States, it is estimated that in 2013, 17,990 people will be diagnosed with 
esophageal cancer, and greater than 85% of those diagnosed will succumb to the disease. One of 
the significant problems EAC patients face is that diagnosis tends to occur at an advanced stage, 
resulting in an overall poor 5-year survival rate of less than 15% 1. There are some common risk 
factors for EAC incidence, such as a history of gastro-esophageal reflux disease (GERD), 
obesity, male gender, Caucasian and over the age of 402. Many patients with EAC also have 
associated Barrett's esophagus (BE). BE is a predisposing condition where the normal squamous 
of the esophagus is replaced by a columnar intestinal-type epithelium, yet, only around 1% of 
patients with BE are estimated to develop EAC3. There is currently no molecular marker(s) that 
effectively identify patients at highest risk for development of EAC. The current clinical practice 
for detection of EAC is by screening patients with high-risk GERD using an endoscopic-based 
sampling of the metaplastic tissue and characterization of the degree of dysplasia in the biopsy 
samples by pathology4,5. Once enrolled in the screening program they undergo endoscopic-
biopsy every three months to two years depending on the degree of dysplasia. During the 




and evaluated for histologic dysplastic changes by expert pathologists4,5. Even though some 
studies have shown that this method is associated with detection of EAC at an earlier stage, 
improving patient outcome7, one of the problems with this approach is the random sampling of 
the endoscopic biopsies which may miss small regions of HGD or EAC.  
Our group has suggested a more targeted approach, where we develop fluorescently-
labeled peptides that can target the cancer cells. Importantly, a recent study by our group shows 
the potential for detection of EAC in vivo in human patients, through the use of fluorescently-
labeled peptides detected by endoscopy after administration of the peptide into the esophagus8. 
This new method of detection can be used to detect tumors located in the distal esophagus and 
gastric cardia and we have begun to identify additional cell surface proteins that can be targeted 
by fluorescent peptides for early cancer identification.  
Using transcriptional profiling of BE progression and analysis of cellular processes we 
show, first, that BE progression is associated with loss of mucin, increased ATM-DNA damage 
response, and increased splicing. Secondly, we identify two molecular targets (C3 and HLA-
DRB5) that significantly distinguish HGD/EAC tissue when compared to non-dysplastic BE. 
Additionally, we show that these candidates are over-expressed in EAC and GEJAC tumors 
when compared to normal tissue. In conclusion, we propose these candidates for future peptide 
target development of the HGD/EAC tissue.  
Results 
Transcriptional Profiling of Barrett’s Metaplasia, Dysplasia, and Esophageal 
Adenocarcinoma Progression 
EAC is known to arise from the dysplastic progression of BE (Figure 3.1a). Therefore, to 




cryostat-sectioning and macro-dissection of the mucosa in BE. We collected samples 
representing non-dysplastic BE, BE containing different degrees of dysplasia, and EAC samples 
with >70% tumor cells (BE n=5, LGD n=20, HGD n=29 and EAC n=11). These samples were 
carefully characterized by a pathologic review preformed by Dr. Scott Owens.  The percentage 
of each histology in 10% increments for each BE sample was defined (Figure 3.1b). The macro-
dissected sections were used to extract mRNA and we then performed RNA-sequencing (RNA-
seq), a comprehensive method for the analysis of the whole transcriptome9 in this large cohort of 
pathologically confirmed non-dysplastic, LGD, HGD and EAC tissues (n=66). In addition to the 
RNA-seq cohort, we examined our previously published progression cohort, where we had BE-
LGD-HGD and EAC samples examined by Affymetrix arrays (n=46). Using these 
complementary methods, we proceeded to identify the pathways that are deregulated in BE-
dysplastic progression to cancer and characterize the potential reasons for the deregulation of 
these pathways. In addition, we identify cell surface coding genes that are over-expressed in 
HGD/EAC.  
Pathway analysis: Spliceosome. 
 After organizing the samples by the degree of dysplasia to EAC (Figure 3.1b), we 
correlated the expression values (RPKM) for the whole gene transcripts (n=57,284) per sample 
to the degree of dysplasia (Figure 3.2a). We identified that 954 genes show positive correlation 
and over-expressed in HGD and EAC relative to BE and LGD (Figure 3.2a right panel). We also 
observed 1,193 genes that are negatively correlated with BE progression to EAC and are 
decreased in expression in HGD and EAC as compared to BE and LGD (Figure 3.2a left panel). 
This progression set nominates the genes that are progressively being over-expressed/down-




deregulated in progression, we performed pathway analysis using DAVID-genome browser. We 
identified spliceosome as the top pathway increased during BE progression to EAC (Figure 
3.2b). We confirmed that many of the spliceosome-related genes are also increased using the 
independent cohort of BE to EAC samples analyzed using Affymetrix arrays (Figure 3.3a-b), 
thus supporting the observation of increased spliceosome pathway during progression of BE to 
EAC.  
 The spliceosome machinery is a large complex of proteins responsible for removing 
introns from transcribed pre-mRNA, and creating isoform diversity. To determine if the splicing 
machinery is hyperactive in the progression of BE to EAC, we utilized the RNA-seq data, and 
determined isoform specific expression levels in collaboration with Dr. Hui Jiang and correlated 
them to the splicing over-expressed genes. We observed a total of 194,872 isoform specific 
transcripts (Figure 3.4a, blue circle). The total cohort of splicing machinery-coding genes is 
comprised of 35 genes (Table 3.1). We calculated a z-score to represent the overall level of 
expression per sample. We further identified the number of isoforms differentially expressed per 
sample, and calculated an isoform diversity score. We observed a significant correlation of 
splicing with increased isoform diversity from BE to EAC (r = 0.04787, P = 4.792e-05)(Figure 
3.3c). Further, we characterized the isoforms that are positively or negatively correlated with 
dysplastic progression (Figure 3.4). We observed 886 isoform transcripts that significantly 
change during progression (P <0.05)(Figure 3.4a, yellow circle). Figure 3.3b depicts an 
example of a gene transcript, RNF128, which has three isoforms. Two isoforms of RNF128 show 
unique expression in the progression (Figure 3.3b, top and middle panel), and one isoform has 
non-detectable levels of mRNA (Figure 3.3b, bottom panel). We assessed whether isoforms of 




expression of those isoforms in the dysplastic progression. We identified 241 isoforms depicting 
a “switch” between their isoforms (Figure 3.4a, green circle). Of those, we identified the 
isoforms that show a significant “switch” and are correlated to progression, with RNF128 
isoforms being one of the most significant (Figure 3.4a, orange box)(Figure 3.4d). Together, 
these observations support a role of splicing and increased isoform diversity in the dysplastic 
progression of BE to EAC.  
Loss of mucin and activation of the DNA damage response.  
We have established that splicing and isoform diversity is increased in HGD and EAC, 
but the potential mechanism or activator of the splicing machinery leading to more isoform 
diversity is currently unknown in the context of BE progression to EAC.  Recently, the core 
spliceosome has been found to be a target and effector of non-canonical ATM signaling10. 
Therefore, we further examined the potential events associated with increased spliceosome 
activity in BE to EAC progression.  
A mucus barrier is responsible for the protection of epithelial cells in the context of BE 
mucosa, that represent the intestinal type cells that are known to be at most risk of developing 
into dysplasia. We observed that the mucin genes (MUC5B, MUC3A, MUC17) are significantly 
decreased in both RNA-seq and Affymetrix cohorts (Figure 3.5a-c) with a corresponding loss of 
goblet cells in LGD and especially HGD (Figure 3.5e, arrows) seen in histopathologic 
preparations (H/E sections) (Figure 3.5d-e). Concurrent with the loss of mucins, which 
functionally protect cells against acid/bile reflux induced cellular damage, we observe increased 
mRNA expression of ATM, MRE11, P53BP1, and RAD50 (Figure 3.6a-d) in BE progression 
suggesting activation of the “DNA damage response” (DDR). We further assessed the activation 




3.7). We observed γH2AX increased positive staining of dysplastic BE cells but not non-
dysplastic glands (Figure 3.7a, bottom panel). We further assessed the levels of mucin stains 
using alcian blue-periodic acid Schiff reagent (Figure 3.7). After staining for mucin, in BE 
tissue, we observe high mucin staining in BE and in mucin producing glands. This staining is 
reduced or lost in dysplastic areas that also show abundant apoptotic cells (Figure 3.7, top 
panel). Importantly, IHC analysis with γH2AX reveals increased positive staining of dysplastic 
BE cells but not in non-dysplastic glands. This suggests that loss of protective mucins in 
dysplastic BE may lead to DNA damage and initiate phosphorylation of H2AX by the ATM 
kinase.  
Identification of cell surface markers for HGD. 
The presence of BE is often associated with esophageal adenocarcinoma (EAC)11–15. 
Patients with BE have an estimated 30 to 40-fold greater risk of developing EAC than the 
general population12,13. Diagnosis of EAC often occurs at an advanced stage resulting in an 
overall poor 5-year survival rate of less than 15%. The current clinical practice for detection of 
early EAC consists of Barrett’s patients having multiple biopsies taken by endoscopy and 
pathological characterization of the degree of dysplasia in each biopsy. This current method has 
the serious limitation of random sampling which can miss the exact location where dysplastic 
and/or cancer cells are arising. The malignant potential of this condition is evidenced by the 
progression of non-dysplastic BE to LGD, HGD and finally to invasive EAC. Most studies have 
shown that at the time of HGD removal, there is pathological evidence of EAC present within 
the HGD. Therefore, patients with HGD are the most ‘at risk’ for developing EAC. Detection 
and identification of molecular markers that can identify the high-risk patients could potentially 




improve patient outcome. 
By utilizing cell surface fluorescent peptides targeted at cancer rising cells, we can 
greatly improve the BE biopsy sampling error8. Since HGD represents the tissue with highest 
cancer risk, we utilized the RNA-seq progression cohort to identify cell surface coding genes that 
are over-expressed in the HGD/EAC cells when compared to non-dysplastic BE or LGD.  
We performed an analysis of variance (ANOVA) across all transcript (n=57,284) in the 
BE-EAC progression and we identified those that were overexpressed in HGD when compared 
to non-dysplastic BE (n=954) (Figure 3.8a-b). Each transcript/gene was annotated using gene 
ontologies for ‘plasma membrane’ and/or “integral to plasma membrane” (n=4,000) coding 
genes which resulted in n=134 candidates that were both overexpressed in HGD (p<0.001, 
FC>2) and potentially located on the cell surface (Figure 3.9a-b). We identified two candidate 
genes (C3 and HLA-DRB5) that were overexpressed in HGD and EAC when compared to BE 
and LGD (Figure 3.9a-b, top panel, Figure 3.10a-b, top panel, respectively). In addition, we 
looked at the expression levels of C3 and HLA-DRB5 in our previously published cohort, of 
normal (esophagus and gastric) vs. EAC/GEJAC16. Figure 3.11a-b, top panel, shows that HLA-
DRB5 and C3 are over-expressed in EAC/GEJAC when compared to normal tissue (FC>1.5, 
P<0.01).  Finally, sensitivity vs. specificity analysis showed that both, C3 and HLA-DRB5, 
mRNA have a significant capability to distinguish HGD/EAC when compared to BE/LGD 
(mRNA comparisons of HLA-DRB5: ND-BE/LGD vs. HGD/EAC ROC: 0.6629, P=0.0240; ND-
BE vs. HGD/EAC ROC=0.6863, P=0.0166; ND-BE vs. HGD ROC=0.7899, P=0.0029) (Figure 
3.10b, bottom panel). From both candidates, C3 showed the most significant in sensitivity vs. 
specificity (mRNA comparisons of C3: ND-BE/LGD vs. HGD/EAC ROC: 0.7647, P<0.0002; 




(Figure 3.9b, bottom panel), nevertheless, both markers show significance in ROC analysis 
when we performed a more restricted analysis with just non-dysplastic BE and HGD (HLA-
DRB5 ND-BE vs. HGD ROC=0.7899, P=0.0029; C3 ND-BE vs. HGD ROC=0.8229, P=0.0002) 
(Figure 3.9b-3.10b). We further assessed the mRNA levels of HLA-DRB5 and C3 in our 
previously published cohort of the normal esophagus and gastric tissue vs. EAC/GEJAC16. We 
observed that both HLA-DRB5 and C3 are significantly over-expressed in EAC/GEJAC when 
compared to normal tissue (esophagus and gastric) (P <0.0001) (Figure 3.11 a-b). Even further, 
ROC analysis between normal vs. tumor shows that HLA-DRB5 and C3 mRNA expression 
significantly distinguishes between normal tissues vs. EAC/GEJAC. (ROC= 0.7530, 0.8974; 
P=0.0028, P < 0.0001, respectively). Finally, we used data from the publicly available domain 
Human Protein Atlas17,18, to show that in gastric cancer, both HLA-DRB3 and C3, have high 
protein expression and this expression localizes mainly to the cytoplasm/membranous (C/M) 
location (Figure 3.9-3.10c-d). Altogether, we show that C3 and HLA-DRB5 are over-expressed 
cell surface coding genes with significant ROC curves to distinguish HGD/EAC from BE/LGD. 
Discussion 
Up-regulation of Splicing Coupled with Decreased Protective Mucins and Activation of the 
ATM/DNA Damage Response in BE Progression to EAC 
It is known that BE progresses to low-grade dysplasia, high-grade dysplasia and then to 
invasive esophageal adenocarcinoma. Significant genomic instability, high alterations of copy 
number, and a high rate of TP53 mutations are all molecular events that characterize EAC from 
other cancers19–23. Here, using two independent patient cohorts and (Affymetrix arrays (n=46) 
and RNA-seq (n=66) to examine gene expression during the progression of BE to EAC, we have 




dysplastic progression from BE to EAC. It has been observed in other cancers (such as breast, 
lung, and ovary), that splicing-associated genes were indeed expressed in tumors when compared 
to normal tissue 24. These studies did not previously show any association of splicing with more 
isoform diversity. Therefore, our comprehensive analysis, using RNA-seq, provides new insights 
into the spectrum of diversity and the level of isoform expression in the context of BE dysplastic 
progression to EAC.  This diversity may allow BE cells to survive under stress for multiple 
sources such as reflux, inflammation or other causes. 
Further, we show the loss of protective mucin and an increase in DDR pathway is 
associated with the progression of BE to EAC. ATM has been recently implicated in the 
regulation of splicing 10. This suggests that loss of protective mucins in dysplastic BE may lead 
to DNA damage and initiate phosphorylation of H2AX by the ATM kinase. As reported 10, the 
core spliceosome is a target and effector of non-canonical ATM signaling. Thus we suggest that 
increased spliceosome pathway during BE progression to EAC reflects both DNA damage and 
ATM-dependent signaling events in dysplastic BE cells. 
In the future, investigation of the function of the differential isoforms, as well as 
mechanistic characterization of the direct role of ATM in splicing activation, may lead to 
potential therapeutic approaches, or preventive strategies for reducing BE progression into EAC. 
Since we observed an increase in DNA damage and splicing, one potential approach will be to 
treat esophageal Barrett’s cell lines, with both DNA damage inducing agents, as well as, bile 
acid. Using RNA-sequencing we will look at the differential isoform patterns of the treated vs. 
non-treated. We expect to see an increase in DNA damage response genes, such as RAD50, 
TP53BP1, MRE11, and ATM, as well as, an increase in the isoform diversity pattern of the cells 




Identification of cell surface markers for HGD. 
The current clinical practice for detection of early EAC consists of Barrett’s patients 
having multiple biopsies taken by endoscopy and pathological characterization of the degree of 
dysplasia in each biopsy. This current method has the serious limitation of random sampling 
which can miss the exact location where dysplastic and/or cancer cells are arising. Dr. Wang in 
collaboration with our group, has suggested a more targeted imaging-based approach, where we 
develop fluorescently-labeled peptides that bind to highly overexpressed cell surface proteins 
found in cancer cells. In a recent first in-human patient study, our group demonstrated the 
potential for cancer detection of EAC in vivo 8. The approach utilized phage display technology 
to identify peptides that bind specifically to the plasma membrane of human H460 cancer cells. 
Confirmation of specific binding was performed using ex vivo resected human esophageal 
specimens containing HGD and EAC. This imaging-based approach greatly reduces the issue of 
random sampling. 
Here, we have proposed two cell surface coding genes, C3 and HLA-DRB5, for the 
detection of HGD. We show that C3 and HLA-DRB5 are over-expressed in the HGD and EAC 
tissue. Most studies have shown that at the time of HGD removal, there is pathological evidence 
of EAC rising within the HGD25. Therefore, patients with HGD are the most ‘at risk’ for 
developing cancer26. Although future validation and tissue microarrays are needed, we suggest 
that C3 and HLA-DRB5 coupled with endoscopy could be used as detection markers to identify 
the high-risk epithelium and potentially help in the diagnosis of the EAC at the earliest stage of 
cancer development. In addition, it would enhance the current methods of EAC diagnosis and 
hopefully eradicate the sampling error that current surveillance programs face. This could 




protocols enrolling patients in the screening program requires biopsies of the esophagus for 
assessment of the degree of dysplasia. Our targeted approach would allow stratification of 
patients at greatest ‘risk’ of developing cancer from those at lower risk, therefore; only patients 
that are at greatest risk would require close monitoring. 
The identification of molecular markers for endoscopic imaging that identify patients at 
‘high-risk’ for developing cancer is innovative and a new strategy that could improve current 
medical procedures monitoring patients with BE and improve patient outcome.  This method 
may be able to increase the overall 5-year patient survival of patients with EAC, which is 
currently very low. 
Materials and Methods 
Patient tissues. 
Samples were obtained following informed patient consent according to the approval and 
guidelines of the University of Michigan institutional review board. Tissues were obtained from 
patients undergoing esophagectomy for adenocarcinoma within the University of Michigan 
Health System between 1991 and 2012, without preoperative radiation or chemotherapy. All 
specimens were collected fresh and frozen in liquid nitrogen and stored at -80 C until use, and 
with regards to EAC patients, collected prior to any preoperative radiation or chemotherapy. 
Cryostat sections of Barrett’s mucosa allowed the careful macro-dissection of the 
epithelium prior to isolation of mRNA and DNA. Tissues from patients undergoing resection for 
HGD or EAC were histopathologically characterized 27 for the percentage of low-grade (LGD) 
or high-grade dysplasia (HGD) in 10% increments. 




RNA was isolated from the matching samples used for pathologic review. mRNA 
extraction was performed using QIAzol Lysis Reagent (Qiagen, Valencia, CA) and purified with 
RNeasy spin columns (Qiagen), including on-column DNAse I incubation, according to the 
manufacturer's instructions. RNA samples with RIN scores greater than 7.0 (Agilent 
Bioanalyzer; Agilent Technologies, Palo Alto, CA) were submitted to the University of Michigan 
Sequencing Core. Paired-end sequence analysis of 120 million 100bp reads per lane using 
Illumina sequencers was used per sample. Strand-specific RNAseq libraries were prepared 28. 
RNA sequencing. 
Hui Jiang, Ph.D. developed the pipeline for defining the gene expression levels28. 
Sequence alignment was performed using Bowtie (0.12.8) which was supplied with the set of 
transcript models annotated in the Homo sapiens ensemble database version 72 (GENCODE 
v.17) with 57,281 annotated genes and 194,871 annotated transcripts. Read alignment was 
performed for all 66 samples, a total of 3.7 billion, strand-specific read pairs (i.e., 7.4 billion 
reads) were sequenced, resulting in 2.5 billion (68%) read pairs that aligned uniquely (range: 26-
51 million; median: 36 million). Quantification of gene and transcript expression levels was 
performed using rSeq (0.1.0) and defined as RPKM (reads per kilobase of exon model per 
million mapped reads) unit. Statistical analysis was performed on log-transformed expression 
levels [log(RPKM+1)] to avoid taking the logarithm of zero. Data analyses included two sample 
t-test and Wilcoxon rank-sum test between BE and LGD vs. HGD and EAC as well as between 
BE and EAC and Spearman correlation test between gene expression levels and disease 
progression grades. Wilcoxon rank-sum tests were more powerful than t-tests for this data set 




BE and LGD vs. HGD and EAC was summarized as the ratio of the median expression levels 
between the two groups. False discovery rates (FDR) were computed using Storey’s method.  
Immunohistochemistry.  
Tissue sections were cryostat and mounted. We proceeded to stain using the monoclonal-
mouse antibody for γ-H2AX (Cat. No 05-636- Anti-phospho-Histone H2A.X (Ser139), clone 
JBW301, Millipore). The monoclonal antibody was used at dilutions of 1:500, after microwave 
citric acid epitope retrieval for 20 minutes and lightly counterstained with hematoxylin. 
Pathway analysis.  
We correlated the level of the transcripts to the progression of dysplasia and identify two 
groups, one group with positive correlation (n=954) and a group with negative correlation 
(n=1,193) (Figure 3.2). We performed enrichment testing, for the positively or negatively 
correlated gene transcripts. We performed enrichment testing using the DAVID website with the 
appropriate platform-specific background gene list (“HuEx-1_0-st-v2”) and default algorithm 
settings. Individual ontology categories with false discovery adjusted (Benjamini) p values <0.05 
were reported.  
Isoform Diversity  
Dr. Hui Jiang descries that the score measures how evenly distributed the transcript 
expression levels are, therefore, the more evenly distributed the higher the score. The score takes 
its maximum value when all the transcripts have the same expression level. In contrast, it takes 










Figure 3.1 Tissue characterization for dysplastic progression of BE to EAC (a) Tissues from 
patients undergoing resection for HGD or EAC were histopathologically characterized for the 
percentage of low-grade (LGD) or high-grade dysplasia (HGD) in 10% increments. Arrows 
indicate the HGD tissue/cells are frequently localize in the surface of the epithelium. (b) 68 BE 
tissues from patients undergoing resection for either HGD (n=29) or invasive EAC (n=11) were 
utilized for RNA-seq, histologically characterized, and organized based on the percentage (%) of 
HGD. The LGD samples are also organized by increasing percentage of LGD however only the 
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Figure 3.2 Pathway analysis in BE dysplastic progression to EAC (a) Identification of 
transcripts over-expressed (n=954) and down-regulated (n=1193) in the progression from BE to 
EAC. These transcripts were used for pathway analysis, using DAVID-genome browser (b-c) in 
BE progression to EAC and reveals spliceosome (b) as the top increased pathway and 
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Figure 3.3 Splicesome and isoform diversity in BE dysplastic progression to EAC (a) 
RNAseq and (b) Affymetrix array (46 BE-EAC samples) analysis showing individual increased 
spliceosome genes during progression of BE to EAC. Affymetrix array of genes with increased 
expression are shown in yellow. (c) Bioinformatics analysis of RNA-seq data for isoform-variant 

















Figure 3.4 Identification of Isoform specific transcripts that “switch” during BE dysplastic 
progression to EAC (a) Using RNA-seq data we calculated RPKMs for isoform specific 
transcripts (n=194,872), (b) depicts the RPKM of RNF128 and its three different isoforms. Only 
two were expressed. We calculated the ratio of each isoform to whole gene transcripts, with (c) 
depicting RNF128 ratios and correlation to BE dysplastic EAC progression. We observed (a- 
yellow) 886 isoform transcripts, which correlate to progression. We further assessed whether any 
of these isoforms show a “switch” (one isoform going up and/or one going down in BE à EAC 
progression (c). We identify 16 genes that have different isoforms that show a “switch” in 
progression (a-orange), with (d) RNF128 isoform showing a “switch” in isoform expression in 












































































Figure 3.5 Loss of mucin production in BE progression (a) Affymetrix and (b-c) RNA-seq 
analysis showing reduced mucin gene expression (MUC5AB, 3A, 17) in progression of BE to 
EAC and particularly in HGD and EAC. (d-e) Loss of mucin gene expression is consistent with 



































































Figure 3.6 Increased expression of genes that are part of the DNA Damage Response  
(a-d) Over-expression of the ATM/DNA damage response (DDR) pathway genes (ATM, MRE11, 












































































Figure 3.7 Phosphorylation of H2AX (γ-H2AX) in HGD (a) Top panel- Mucin staining: 
abundant blue mucin is present in non-dysplastic BE goblet cells but are lost in dysplastic BE 
cells. Bottom-panel- γ-H2AX nuclear staining is detected in dysplastic but not non-dysplastic BE 
cells. Non-dysplastic BE cells clearly show basally located nuclei, mucin-positive goblet cells 
present, whereas the dysplastic BE cells in neighboring glands have disorganized, stratified 



























Figure 3.8 Schematic of methods utilized to identify cell-surface over-expressed genes in 
HGD and EAC (a) 66 total samples were used for RNA-sequencing (BE n=6, LGD n=20, HGD 
n=29, and EAC n=11). (b)(top panel) After RNA sequencing we obtained a total of 57,284 gene 
transcripts. We manually curated/correlated the transcripts showing an increase in mRNA during 
progression from BE to EAC (b: bottom panel). (c) We observed a total of 954 transcripts that 
correlated with progression (BE à EAC). (d) To identify the genes that code for cell surface 
protein, we use gene ontologies (GO) terms for plasma membrane and integral to plasma 
membrane. We identified 134 genes that are cell surface and that correlated with progression 






























































Figure 3.9 C3 expression (a) in BE dysplastic progression to EAC (% of HGD displayed by the 
red dots, red line reflects 100% EAC samples). (b) Analysis of mRNA expression and sensitivity 
vs. specificity of C3 between different stages of progression (ND-BE, LGD, HGD, and EAC). 
(c) Protein expression of C3 in normal and stomach (d) Quantification of number of samples for 
intensity, quantification, and location (C=cytoplasm, M=membranous, N=nuclear) of C3 protein 
in gastric/stomach cancers. (d and c data were obtain from the publicly available data domain 
















































































































































































Figure 3.10 HLA-DRB5 expression (a) in BE dysplastic progression to EAC (% of HGD 
displayed by the red dots, red line reflects 100% EAC samples). (b) Analysis of mRNA 
expression and sensitivity vs. specificity of HLA-DRB5 between different stages of progression 
(ND-BE, LGD, HGD, and EAC). (c) Protein expression of HLA-DRB5 in normal and stomach 
(d) Quantification of number of samples for intensity, quantification, and location (C=cytoplasm, 
M=membranous, N=nuclear) of HLA-DRB5 protein in gastric/stomach cancers. (d and c data 




















































































































































































Figure 3.11 HLA-DRB5 and C3 expression in normal (NE/NG) vs. tumor (EAC/GEJAC) (a-
b, top panel) HLA-DRB5 and C3 over-expression in EAC/GEJAC when compared to normal 
tissue (esophagus and gastric) (P <0.0001). (a-b, bottom panel) ROC curves of HLA-DRB5 and 
C3 mRNA expression significantly distinguishes between normal tissues vs. EAC/GEJAC. 
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Esophageal adenocarcinoma primarily affects Caucasians (Cau) but not African 
Americans (AA), despite both having a similar incidence of risk factors. Therefore, we 
hypothesize that the normal esophageal squamous mucosa in AA has protective mechanisms 
against GERD-induced damage that differ from Cau. We used Affymetrix ST 2.1 expression 
arrays to determine the transcriptional differences between 40 normal AA and CAU esophageal 
squamous mucosa (NE) tissues (24 with no disease and 16 presenting with a history of GERD, 
Barrett’s esophagus (BE) and/or EAC). Despite minimal differences between the non-diseased 
NE expression profiles, we identified that a detoxifying enzyme, GSTT2, is significantly over-
expressed in AA compared to Cau. Two genomic events, a 30kB deletion and a 17bp promoter 
duplication in the GSTT2 locus, previously associated with lower expression of GSTT2, were 
also found to correlate with lower GSTT2 expression in EA compared to AA. These observations 
were validated using matched genomic sequence and expression data in lymphoblasts from the 
1000 Genomes Project. In addition, we identify that the 17 bp promoter non-duplication is highly 
conserved in African and African decent populations. Furthermore, we demonstrate that GSTT2 
is important in the protection of esophagus squamous cells against DNA damage when exposed 




suggest that increased GSTT2 expression may protect against damage caused by GERD and 
underlie the low incidence of EAC in AA. 
Introduction 
EAC is known to arise from a metaplasia tissue known as Barrett’s esophagus (BE), a 
pre-disposing condition where the normal squamous of the esophagus (NE) is replaced by 
columnar intestinal type tissue. It has been extensively observed that EAC primarily affects 
Caucasians (Cau) but not African Americans (AA), despite having a similar incidence of the key 
risk factors: obesity, gastroesophageal reflux disease (GERD), and smoking1,2. More importantly, 
it is known that the primary risks factors including GERD, and obesity,3–6 do not differ between 
the two ethnic groups7–9. Nevertheless, AA show less frequent erosive esophagitis than Cau 
(24% vs 50%, P =0.03)9 in addition to a much lower incidence of EAC in this population (AA). 
There is a lack of understanding as to why the AA population has less erosive esophagitis and 
therefore a lower incidence of developing EAC.  
Transcriptional profiling is the measurement of the entire RNA transcript in a given cell 
or tissue that is encoded by DNA. We sought to understand the transcriptional (RNA) profile of 
the normal squamous mucosa of individuals of both populations (Cau vs. AA). Further, we 
included populations of individuals: disease free (no-history of GERD, BE, and EAC), and 
diseased individuals (long history of GERD, the presence of BE and development of EAC). Our 
goal was to utilize transcriptional profiling to identify key differences and pathways that might 
contribute to the protection of the esophagus in AA that the esophagus of Cau may lack.  
Here we report that a detoxifying enzyme responsible for inactivating reactive oxygen 
species and reducing DNA damage10, glutathione-s-transferase theta 2 (GSTT2, GSTT2), is over 




two genomic events in the GSTT2 locus (a 30kb deletion11 and a 17bp promoter duplication12), 
that negatively affect GSTT2 mRNA expression, are highly frequent in the Cau population. The 
promoter non-duplication is associated with high levels of GSTT2 mRNA and is highly 
conserved in African and African descendant populations. In addition, we show that reduction of 
GSTT2 in an esophageal squamous cell line makes the cells more susceptible to DNA damage 
under genotoxic stress. Together, these observations suggest that increased GSTT2 expression 
may protect against damage caused by GERD and underlie the low incidence of EAC in AA. 
Results 
Transcriptional Profile of Normal Squamous Mucosa in AA vs. Cau   
To determine whether the NE of AA demonstrates a different transcription profile from 
Cau we used Affymetrix ST 2.1 expression profiling analysis. We obtained two specific cohorts 
of NE from AA and Cau. One included healthy individuals (no history of BE or EAC) from both 
ethnic groups (Cau-NE n=12; AA-NE n=12) and the other included the NE of diseased patients 
with a history of GERD and presence of BE and/or EAC (Cau-NE:B n=8; AA-NE:B n=8)(Table 
4.1). We performed analysis of variance (ANOVA) across all groups. When comparing NE 
profiles of AA to Cau only eight genes showed >2-fold change (FC) (P<0.01; Table 4.2), 
suggesting minimal differences in the expression profiles between these two cohorts. The GSTT2 
(mRNA) demonstrated the largest FC (AA-NE vs. EA-NE; P=0.0004, FC=5.1) between NE 
samples of the two ethnic groups, while GSTT2B transcripts demonstrated the fourth largest FC 
(Figure 4.1a; Table 4.2). Since the Affymetrix probesets do not adequately distinguish between 
GSTT2 and GSTT2B transcripts, we therefore present mRNA expression as GSTT2/2B (detailed 
in Methods). We observed a similar, though non-significant (P=0.07) trend of increase 




observations suggest that GSTT2/2B expression is lower in the NE of the normal Cau population 
as well as in individuals who developed BE and/or EAC. We then validated the array results 
using an extended cohort of non-diseased squamous samples (AA-NE n=21 vs. Cau-NE n=21) 
with reverse transcription followed by quantitative real-time polymerase chain reaction (qRT-
PCR). GSTT2/2B was overexpressed in the NE of AA relative to EA (FC=1.4, P=0.0014; Figure 
4.2a) and correlated with the array data (r=0.80, P<0.0001; Figure 4.2b). Phase II detoxification 
enzymes, including GSTT2, are responsible for conjugating activated endogenous compounds to 
large anionic groups to facilitate active transport and excretion from the cell13–18. GSTT2 has an 
active role in protecting cells against the effects of reactive oxygen species (ROS) and thus 
reducing DNA damage14–18. Given its role in detoxification and our observations of increased 
GSTT2/2B expression in the AA population, we hypothesize that enhanced protection against 
GERD-related DNA damage may underlie racial differences in EAC incidence. 
Genomic events associated with mRNA levels of GSTT2. 
To address further the basis for the differential mRNA expression of GSTT2/2B in AA vs 
CAU we examined the GSTT2 chromosomal region. Resulting from an inverted chromosomal 
segmentation duplication, both genes (GSTT2 and GSTT2B) are located in chromosome 
22q11.23, with DDT and its inverted homolog, DDTL, located between them24 (Figure 4.1b). 
GSTT1, the only other Theta class GST present in humans, shares 55% protein homology and is 
located telomeric to both GSTT2 and GSTT2B24 (Figure 4.1b). Strongly differential expression 
of GSTT2 and GSTT2B (P<0.001) (Figure 4.1a), but not DDT (FC=0.85, P=0.013), GSTTP1 
(FC=0.80, P=0.16), or GSTT1 (FC=0.70, P=0.22), was observed between AA-NE vs. CAU-NE 
(Figure 4.1c-e). This suggests the increased expression of GSTT2/2B in AA is not due to 




specific. We further assessed other genomic events in the chromosome 22q11.23 locus that may 
affect regulation of GSTT2/2B expression. Zhao et al. characterized a 37kb deletion of GSTT2B 
(Figure 4.3a; Figure 4.5a), which is associated with lower levels of GSTT2 expression11. We 
genotyped both AA and Cau normal squamous cohort samples using the method of Zhao et al.11 
and observed a slightly higher frequency (Fisher Exact P=0.03) of the GSTT2B deletion in Cau 
NE (80.6%) relative to AA NE (54.8%; Figure 4.5b). Lower GSTT2 expression was observed 
among individuals harboring homozygous deletions of this gene, though not significantly 
different from those homozygously non-deleted (P=0.10; Figure 4.5c). Indeed using qRT-PCR 
to examine the expression pattern in combination with GSTT2B deletion genotype using 
extended cohorts of NE from AA and Cau individuals show that deletion of GSTT2B cannot 
explain the expression differences between the two populations (Figure 4.5d).  
In a study examining tandem duplications across the genome, Marotta et al. identified a 
17bp tandem duplication within the promoter of GSTT2 and GSTT2B12 (Figure 4.3a). Using a 
luciferase-linked assay to assess promoter function they showed the presence of the 17bp tandem 
duplication associates with lower GSTT2 and GSTT2B promoter activity12. Utilizing a PCR-
based methodology to differentiate the 17bp promoter duplication, we genotyped gDNA from 
the Cau and AA samples. We observed a significantly higher frequency (Cau NE vs. AA NE: 
97.5% to 67.5%, P<0.00067) of the promoter duplication in Cau relative to AA (Figure 4.3b; 
Figure 4.4a-b). We then examined matched lymphoblast genotype and mRNA expression data 
available for a subset of the 1,000 Genomes Project samples25 and confirmed those individuals of 
African descent have higher expression of GSTT2 mRNA than Cau/European populations 
(P=0.030) (Figure 4.6a). Furthermore, we confirmed that GSTT2 promoter duplication levels 




(P=0.0058; Figure 4.3c) and in the 1000 Genomes cohort (P=1.5x10-6; Figure 4.6b). The 
GSTT2B deletion also strongly correlated with GSTT2 expression in the 1000 Genomes data 
(Figure 4.6c), however, the most important contribution to low GSTT2/2B expression occurs 
when the 17bp GSTT2/2B promoter duplication is homozygous (Figure 4.6d) and thus similar to 
the results seen in the esophagus (Figure 4.3d). In both sample sets the 17bp promoter genotype 
status provided a much better explanation for GSTT2/2B expression variance than ethnicity. 
These results suggest the presence of the promoter duplication is more frequent in Cau than AA 
and may underlie reduced esophageal GSTT2/2B expression in this population. In terms of 
potential confounding effects, we did not observe any significant differences in GSTT2/2B 
mRNA levels between males and females (Figure 4.7a, b) or in relation to the presence of 
GERD or smoking status (Figure 4.7c, d). It is of interest to note that El-Serag et al.9 examined 
variation in the prevalence of GERD within US populations and reported no difference in the 
frequency of GERD symptoms (weekly heartburn and/or regurgitation) between different racial 
groups (AA 29%, Cau 28%, other 25%, P=0.80). However, AA participants had a much lower 
risk of esophagitis (adjusted OR 0.22–0.46, P<0.001)9, which translates into reduced tissue 
damage for comparable reflux exposure. 
Validation of genomic events associated with GSTT2 expression using 1000 genomes 
data. 
We used 1000 Genomes data to examine the distribution of the 17bp GSTT2/2B promoter 
duplication status across world populations. The 17bp GSTT2/2B promoter duplication is 
prevalent in the other super-populations (AMR=94%, EUR=95%, SAS=95% and EAS=97%) 
when compared to AFR (AFR=73%) (chi2 P<0.01; Figure 4.8a). In particular West African 




general had average 17bp GSTT2/2B promoter duplication frequencies of 1-5%) (Figure 4.8b; 
Table 4.3).  
GSTT2 functions to prevent DNA damage in cells undergoing genotoxic stress.  
In the esophageal field, there is a lack of normal esophagus cell lines, with only one 
immortalized esophagus squamous cell line known as HET1A. Therefore, we utilized additional 
cell lines of squamous lineage to assess GSTT2 genotype, mRNA, and protein levels.  To identify 
the effect of the number of GSTT2 gene copies and the presence of GSTT2 promoter duplications 
we genotyped a cohort of cell lines including the normal squamous esophagus (HET1A), and a 
variety of different squamous cancers (head and neck, and cervical cancer) as well as 
adenocarcinomas (Figure 4.9a). 
We observed that the normal esophagus cell line (HET1A) is homozygously deleted for 
the 37KB fragment, indicating that it only harbors 2 copies of the GSTT2 gene (Figure 4.9a, top 
panel). On the other hand, HeLa cells are homozygously non-deleted, and therefore harbors 4 
copies of GSTT2 (Figure 4.9a top panel). We further assessed whether these gene copies of 
GSTT2 harbor the promoter duplication. HET1A is homozygous and HeLa is heterozygous for 
the promoter duplication, respectively (Figure 4.9a bottom panel). Although both cells lines 
were immortalized from African Americans, based on our current observations, HET1A 
represents the genotype most frequently observed in the Cau population whereas HeLa cells 
represent a predominantly AA genotype. We further evaluated both the mRNA and protein levels 
of GSTT2/GSTT2 in HeLa and HET1A. As expected, we observed that HeLa cells have higher 
levels of endogenous GSTT2 (both at the mRNA and protein levels), with over 2-fold higher 
levels than HET1A cells (Figure 4.9b-c).  GSTT2 has been previously shown to protect cells 




OOH)20. Based on these observations and the endogenous levels of GSTT2 in the cell lines, we 
hypothesized that HET1A cells will be more susceptible to DNA damage when exposed to cum-
H2O2 than HeLa cells. DNA damage was measured using immunofluorescence staining of DNA 
double-strand break marker, gamma-H2AX (γ-H2AX) and quantification of nuclear foci 
(Methods). First, we determined the efficiency of cum-OOH in producing DNA damage and the 
cellular toxicity threshold, by performing increasing dose gradient (0, 18, 25, 75, 100, 150µM) 
and time course (30min, 1hr, 2hr) experiments. We observed >50% DNA damage formation 
(cells with >10 γH2AX foci) in HET1A cells treated with 100µM cum-OOH for 1hr and without 
cell death. We then treated HET1A and HeLa cells with 100µM cum-OOH for 1hr and stained 
for γH2AX and DAPI (nuclei stain). Under this genotoxic stress using cum-OOH treatment, 
HET1A cells showed >20% more DNA damage than HeLa cells (Figure 4.9d-c). Altogether we 
identified that the GSTT2 genotype associates with the level of GSTT2/GSTT2 mRNA and 
protein in cell lines, and cells with higher expression of GSTT2 sustain less DNA damage under 
similar genotoxic stress conditions when compared to low GSTT2 expressing cells (Figure 4.9d-
c).  
 We compared two cell lines with different endogenous levels of GSTT2 and found that 
HET1A is more susceptible to DNA damage from genotoxic stress than HeLa. It is important to 
highlight that this comparison is made between a normal cell line and a cancer cell line, 
therefore, the lower DNA damage observed in HeLa may be influenced by cancer-related factors 
(more resistant to treatments), than GSTT2 specific factors. To elucidate if GSTT2 plays a role 
in protecting cells against genotoxic stress in HET1A and HeLa, we performed knockdown 
experiments in both cell lines with and without treatment of cum-OOH. We transfected HET1A 




successful mRNA and protein knockdown of >50-80% in both cell lines (Figure 4.10 a-e). We 
observed that after knockdown of GSTT2, using four different GSTT2 siRNAs, treated cells 
have twice the amount of DNA damage when compared to controls (control, NT). Even further, 
after the knockdown, HeLa cells sustain DNA damage, comparable to HET1A. This data 
suggests that GSTT2 plays an important role in protecting cells against genotoxic stress and that 
the relative levels of GSTT2 associates with the amount of DNA damage the cells sustain when 
exposed to genotoxic stress.  
We further assessed whether increasing the levels of GSTT2 could make cells less 
susceptible to DNA damage. We transfected HET1A cells with a GSTT2-DDK over-expression 
construct for 24hrs and observed significant over-expression at both the mRNA (Figure 4.13a) 
and protein level (Figure 4.13b, top band). After 24hrs transfection we treated the cells with 0 
and 100µM cum-OOH. We first observed that cum-OOH increases GSTT2 expression, both 
endogenously (Figure 4.13c) and after transfection (Figure 4.13d). We did not observe any 
significant difference in cellular damage with over-expression of GSTT2 but no treatment with 
cum-H2O2 (Figure 4.13e). This suggests that GSTT2 abundance does not impact or induce 
DNA damage in cells. Moreover, we observed that the cells with increased GSTT2 expression 
and receiving cum-OOH treatment contained less DNA damage as compared to negative GSTT2 
cells (Figure 4.13f). In conclusion, we observe that cells containing increased expression of 
GSTT2 and exposed to genotoxic stress and cells with high levels of GSTT2 are less susceptible 
to double strand breaks, than cells negative or low levels of GSTT2.  
GSTT2 protein in NE of AA vs. Cau. 
 We obtained NE tissue from individuals that self-identify as either AA or Cau and in 




squamous tissue (NE) using Western analysis. We observed that GSTT2 is over-expressed at a 
significantly higher frequency in the esophagus of AA (7/8) vs Cau (2/5). Quantification of 
GSTT2 levels normalized to α-tubulin revealed that AA esophagus has greater than 2 FC protein 
expression as compared to Cau (GERD AA vs Cau P=0.0003; GERD-AA vs Non-GERD Cau 
P=0.0002).(Figure 4.14a-b). This data supports the observation that GSTT2 is over-expressed, 
at the mRNA and protein levels, in the esophagus of AA as compared to Cau.  
 Using matched DNA extracted from the blood of the individuals evaluated by Western, 
we evaluated the genotype status for the 37kb deletion and 17bp promoter duplication in the 
GSTT2/2B locus (Figure 4.14c) and compared to the levels of GSTT2 (Figure 4.14d-e). 
Genotype for GSTT2/2B 37kb deletion (-/-)(-/+) and non-deleted (+/+) did not significantly 
associate with levels of GSTT2 protein (Figure 4.14d). In contrast, the GSTT2/2B for the 
promoter duplication (+/+)(-/+) and non-duplicated (-/-) promoter associated with levels of 
GSTT2 protein (Figure 4.14e). In the context of overall genotype for the promoter duplication 
vs. GSTT2 protein levels, we observed that the homozygous-duplicated status correlates with 
both, individuals with high and low GSTT2 expression. Nevertheless, when we divide the 
comparison by the GERD vs. no-GERD, individuals with no-GERD, those with the 17bp 
promoter duplication have less endogenous expression than individuals with no-GERD no 
promoter duplication. In the context of GERD, the genotype does not associate distinctly with 
the levels of GSTT2.   
Esophagus cells treatment with non-steroidal anti-inflammatory (NSAID) 
Indomethacin. 
 NSAIDs have been found to increase the levels of GSTT2 in the esophagus of rats26. 




the levels of GSTT2. First, we assessed the levels by mRNA. We treated HET1A cells with 
indomethacin, with cells given media containing either 300µM or 600µM indomethacin as 
compared to DMSO treated (control). We analyzed the effects of indomethacin in HET1A 
expression (mRNA) at 6, 24, 48, and 72hrs. We observed at the mRNA level, that indomethacin 
induced the levels of GSTT2/2B by up to 15-fold (600µM; 72hrs) (Figure 4.15a). Gene 
expression can be regulated by different mechanisms including epigenetic regulation. Therefore, 
we wanted to assess whether epigenetic activation by tri-methylation of histone 3 at lysine 4 
(H3K4me3) was observed in indomethacin treated HET1A cells. Acetylated or methylated H3K4 
is a marker for transcriptionally active chromatin27, and tri-methylation of lysine residue 27 on 
histone 3 (H3K27me3) is a repressive/silent state28,29. We performed chromatin 
immunoprecipitation (ChIP) assays in HET1A cells treated with 600µM of indomethacin (48hrs) 
or in non-treated cells and measured DNA pull down for three different regions of the GSTT2/2B 
promoter. We observed that after 48hrs of treatment, HET1A shows an enrichment of H3K4me3 
when compared to non-treated controls (P=0.01) (Figure 4.15c).  In addition, we observed an 
enrichment of RNA Pol II at the same sites after indomethacin treatment (P=0.0004) (Figure 
4.15c). In contrast, we do not observe a significant enrichment for the repressive mark 
H3K27me3 (P=0.7339) (Figure 4.15c). The enrichment of H3K3me3 together with RNA Pol II 
correlates with our previous observation of increased expression of GSTT2/2B after treatment 
with indomethacin (Figure 4.15a). Together this data suggests that indomethacin is inducing the 
expression of GSTT2/2B, and epigenetic regulation is playing a role in this activation. 
Nevertheless, we observed that at the protein level, GSTT2 levels did not significantly change 
following indomethacin treatments (Figure 4.15b). This may suggest more potent inducers will 




GSTT2 is a very stable protein it may be that longer incubation times are needed before 
increased protein is detected. It is important to note, that significant changes in GSTT2 levels 
were reported by Van Lieshout et al. when rats were treated with different NSAIDs26, suggesting 
that the potential environment and model for induction of GSTT2 may be important. 
Discussion 
Obesity is a current epidemic in most developed countries. We have observed that the 
incidence of EAC has skyrocketed in the past three decades, and it is more common among the 
Cau than AA. El-Serag et al. and others have reported no difference in the frequency of GERD 
symptoms (weekly heartburn and/or regurgitation) as well as other risk factors including obesity, 
smoking, or age between both ethnic groups7–9. Our current findings provide the first evidence 
for a genetic and a molecular basis to explain this disparity between the two ethnic populations.  
We observed a higher frequency of the 17bp GSTT2/2B promoter duplication in Cau as 
compared to AA and that this is associated with lower levels of NE GSTT2/2B expression. 
Interestingly, lower levels of the related family member GSTT1 has been associated with 
increased esophageal squamous cancer risk in Asian populations33. GSTT2 functions to protect 
cells against genotoxic stress, and in colon cell studies10, it has been observed that having high or 
low levels of GSTT2 contributes to a cell’s susceptibility to DNA damage. Here we report that 
GSTT2 functions in the same manner in the esophagus squamous cell line (HET1A). We 
observed that after knockdown of GSTT2, cells are more susceptible to DNA damage after 
genotoxic stress. Further, we observed that the endogenous levels of GSTT2 (high GSTT2 cell 
line vs. low GSTT2 cell line) influence a cell’s susceptibility to DNA damage under genotoxic 
stress. These observations, suggest that an individual with low levels of GSTT2 and exposed to 
constant genotoxic stress (for example GERD), may undergo more DNA damage than 




Our observation, using 1000 genomes and HapMap data, that the non-duplicated 
promoter is mainly conserved in populations of African descent, suggests a change in selective 
pressure in favor of the duplication when populations migrated from Africa. Our analysis 
indicates that the GSTT2/2B promoter duplication is observed in the Denisovan genome32 
suggesting an ancient derivation that appeared in populations leaving Africa and is now 
distributed worldwide. The higher frequency of promoter duplication might be explained by 
dietary changes necessitated as a consequence of the migration into new ecosystems. This 
change may not have had significant detrimental health consequences until populations more 
recently experienced higher obesity levels and the associated rise in GERD incidence, both key 
risk factors for EAC31. The prevalence of GERD in East Asia is estimated to be 2.5-7.8% while 
populations in the US and Europe, with higher EAC risk, have more frequent GERD (18-28%)31. 
Obesity levels follow a similar pattern, with higher rates among high-risk EAC populations (15-
25%) when compared to lower risk populations in Asia (5-15%)32. These observations suggest a 
potential interaction between lower GSTT2/2B and obesity that may combine to influence an 
individual’s risk for development of the BE and possibly EAC. Thus among non-African 
populations (higher at-risk GSTT2/2B duplicated promoter), obesity rates may offer at least a 
partial explanation for the difference in EAC incidences. If true, then the current trend of 
increasing obesity levels within these populations should be viewed with concern in terms of 
esophageal adenocarcinoma cancer risk. 
Non-steroidal anti-inflammatory (NSAIDs) have been shown to reduce the risk of EAC 
development by >40-50%33. In addition, NSAIDs and apple polyphenols have been observed to 
induce the levels of GSTT210,20,26. Although it has been suggested that the effect of NSAIDs in 




NSAIDs also lower an individual’s risk to GERD-related damage, through increasing GSTT2 
expression as well as inhibiting inflammation.  Further studies looking at the effect of NSAIDs in 
inducing GSTT2 levels in the esophagus are needed to elucidate this hypothesis. Nevertheless, 
treatment with these or other compounds in high-risk populations with GERD may potentially 
increase protective GSTT2/2B and help reduce the increasing incidence of EAC. 
In summary, we report a significant difference in the levels of a key-detoxifying enzyme, 
GSTT2, which is differentially expressed between Cau and AA populations. In addition, two 
genetic variants (37kb deletion and 17bp promoter duplication) negatively associate with the 
levels of GSTT2 and are highly frequent in the Cau population, but not GSTT2 protein levels in 
the contact of GERD. Limitations of this study are the low number of non-GERD samples. 
Although, we have observed that GSTT2 increases when cells are exposed to genotoxic stress 
(Figure 4.13c-d), we cannot differentiate whether the levels of GSTT2 in the AA-GERD group 
are the endogenous, or induced levels due to the presence of GERD. Comparing the Cau and AA 
suggests that there is the potential for this to be an induced state of GSTT2, nevertheless, further 
studies looking at non-GERD individuals from AA and Cau populations will be needed.  
 In conclusion, esophageal squamous cells with low levels of GSTT2 are more 
susceptible to DNA damage following treatments that induce genotoxic stress. Moreover, given 
the potential induction of GSTT2 through treatments with NSAIDs and apple polyphenols, this 
suggests a potential preventive approach for individuals at greatest risk for the disease. 
Altogether, these observations suggest that increased GSTT2/2B expression may be protective 
against esophageal damage caused by GERD and might underlie the low incidence of EAC in 
AA populations. 




Biopsies of the squamous esophagus. 
Histologically normal biopsies of the esophageal squamous epithelium were collected from 
consented men of either AA or Cau ethnicity who underwent a research upper endoscopy 
between 2008 and 2016 at the time of a scheduled colonoscopy performed for colorectal cancer 
screening at the University of Michigan Health System, University of North Carolina or Ann 
Arbor Veterans Affairs Medical Center and found to have no Barrett’s esophagus or erosive 
esophagitis (population controls). Samples from the normal squamous epithelium (NE) of AA 
and Cau individuals who developed BE and/or EAC were obtained from Case Western 
University and Johns Hopkins University and University of Michigan Health System Samples 
were collected between 1991 and 2004 using protocols approved by from their respective 
institutional review boards (IRB). Racial group determination (AA or Cau) was based on the 
results of questionnaires completed by each recruited participant. For normal (NE) tissue from 
EAC patients, none have received preoperative radiation or chemotherapy. All specimens were 
collected fresh and frozen in liquid nitrogen and stored at -80 C until use.  
mRNA extraction and Affymetrix expression analysis. 
RNA was isolated from the normal esophageal squamous mucosa from individuals self-
identified as either Cau or AA. mRNA extraction was performed using QIAzol Lysis Reagent 
(Qiagen, Valencia, CA) and purified with RNeasy spin columns (Qiagen), including on-column 
DNAse I incubation, according to the manufacturer's instructions. RNA samples with RIN scores 
greater than 6.0 (Agilent Bioanalyzer; Agilent Technologies, Palo Alto, CA) were submitted to 
the University of Michigan Sequencing Core for cDNA synthesis and cRNA amplification 
(Ambion WT Expression Kit; Life Technologies, Grand Island, NY), followed by hybridization 




instructions. Expression values for each gene were determined using the robust multi-array 
average (RMA) method34 in the Bioconductor package35 of the R statistical platform. Analyses 
were restricted to the 26,613 coding and non-coding genes for which annotation details were 
available. Analysis of variance was performed across all annotated transcripts. 12 AA without 
Barrett’s (AA-NE), 8 AA with Barrett’s (AA-NE:B), 12 Cau without Barrett’s (Cau-NE), and 8 
Cau with Barrett’s (Cau-NE:B). P values were determined and fold-changes calculated between 
the four groups and compared between races (Table 4.2).  
GSTT2 and GSTT2B Probesets. 
Affymetrix probesets do not adequately distinguish between GSTT2 and GSTT2B 
transcripts, therefore we present mRNA expression as GSTT2/2B and only report the more 
complete 16933088 probeset which covers all 5 exons, rather than 16928115 which only has 
probes on exons 2 and 4. The regulatory and coding sequences of RefSeq genes GSTT2 
(hg38:chr22:23980123-23983911, RefSeq: NM_000854) and GSTT2B (hg38: chr22:23957414-
23961186, RefSeq: NM_001080843) are indistinguishable (99.9% reference sequence homology 
with the difference of a single SNP: rs74487784, which may or may not be unique to the 
GSTT2B form).  
qRT-PCR validation. 
Total RNA from the normal squamous tissue of the 12 AA and 12 Cau examined by ST 
2.1 array, as well as additional normal squamous tissue from 8 AA and 8 Cau were then used for 
real-time (qRT-PCR) validation of selected gene transcripts. Isolated RNA was converted to 
cDNA using reverse-transcriptase following manufacturer’s instructions (Life Technologies, 
Grand Island, NY). RT-PCR reactions were performed in a final volume of 20 µl containing 2 µl 




RNase inhibitor, and 200 ng to 2 µg RNA, depending on RNA concentration after extraction. 
Following RT-PCR the reactions were then diluted to 3 ng/µl prior to qRT-PCR quantitation of 
selected gene transcripts. Primers for qRT-PCR reactions were designed using Primer-BLAST36 
(GSTT2: primers for cDNA Exons 1-2 5’-TGGGCCTAGAGCTGTTTCTT-3’, 3’-
CCAGGCTGTTGATCTGCAAG-5’ and GSTT1 primers for cDNA 5’- 
CTGGAGTTTGCTGACTCCCTC-3’, 3’- GCTCGAAGGGAATGTCGTTCT-5’) or previously 
published (GAPDH and/or B-Actin)37. Optimal annealing temperatures and reaction conditions 
were confirmed using the Cepheid SmartCycler (Cepheid). Samples were run in duplicate using 
the ABI PRISM® 7900HT Sequence Detection System according to the manufacturer’s 
instructions. Thermal cycling conditions consisted of 10min of initial denaturation at 95°C, and 
40 cycles of 15 sec of denaturation at 95°C, and 1min of annealing/extension at 60°C. Relative 
expression and fold-change of the genes of interest (GSTT2 and GSTT1) were calculated by the 
ΔΔ-Ct method (subtracted the average of the Ct’s for the reference gene GAPDH from the Ct 
values of each target gene)38.  
DNA extraction.  
DNA was extracted from cell lines using Qiagen DNeasy Blood & Tissue Kit following 
the manufacturer’s instructions. Genomic DNA was extracted from normal squamous esophageal 
biopsies by adding 800 µl of 100% ethanol to the QIAzol and then spun in a table top centrifuge 
at 4°C for 30min at 1200 rpm. Ten µl of proteinase K (10 mg/µl) and 25 µl SDS (10%) was 
added to each sample and incubated overnight at 56°C. Tris-extracted phenol (500 µl) was then 
added to each sample, gently rotated with inversion at room temperature for 3 hrs, spun at room 
temperature for 20min at 3500 rpm, and the aqueous layer transferred to new tubes. Ice-cold 




Samples were centrifuged at 4°C at 12000 rpm for 15min, air-dried and resuspended in 50 µl TE 
buffer. Samples were then incubated overnight at 4°C and concentration and DNA purity 
determined by absorbance using a NanoDrop spectrophotometer.  
GSTT2B deletion genotype analysis. 
The GSTT2B genotype was determined using a three-primer set for PCR as previously 
described (Zhao et al., 2009): GSTT2B-6858 5’-CACTCAACACAGTAGCCTCATCGTG-3’, 
GSTT2B-6857 5’-TGCCTCCCCTGCCTTATTTC-3’, and GSTT2B-2B 5’- 
CCTTCTGAAATGGAGCCTTTG-3’. The PCR reaction contained a total volume of 50 µl and 
consisted of 25 µl of Promega GoTaq Green Master Mix, 10 pmol of primers GSTT2B-6858 and 
GSTT2B-2B, 15 pmol of primer GSTT2B-6857, and 25 ng genomic DNA. The thermal cycling 
conditions for the reaction consisted of initial denaturation for 2min at 95°C, followed by 35 
cycles of 30 sec of denaturation at 95°C, 30 sec of annealing at 60°C, and 45 sec of extension at 
72°C. PCR products were then separated in 2% agarose gels with ethidium bromide by 
electrophoresis in 1X TBE buffer. Invitrogen’s 100 bp DNA ladder was used as a marker.  
GSTT2/2B promoter duplication analysis.  
Standard PCR using primers and the protocol from Marotta et al (2012) was used. PCR 
products were loaded on 2% agarose gel (Fisher) and run overnight (>18hrs) at 20 V to 
completely separate products. Two examples of each promoter genotype were chosen for 
sequencing based confirmation. PCR products were purified using Qiaquick (Qiagen) columns as 
per manufacturer’s instructions and submitted to the University of Michigan Sequencing Core 
for Sanger sequencing using the reverse primer. Resulting sequence reads were aligned using 
Geneious software (version 5.4.6; Biomatters Ltd, Auckland, New Zealand) (Figure 4.4a) and 




1000 Genomes and HapMap data analysis for GSTT2B and GSTT2 promoter 
genotypes. 
The 17bp promoter duplication is not present in the 1000 Genomes set, primarily because 
of falling in a segmental duplication region but also due to the duplicative nature of the variant 
itself. Nevertheless, the duplication itself can be clearly seen from the raw alignment data 
examined manually. After manual alignment, the duplication appears as a deletion relative to the 
reference sequence (GRCh37). Subsequently, we could not use the 1000GP variant calls and 






We enumerated sequences that mapped around both paralogs, to take into account alignments 
that might align to one or another. We extracted RKPM expression data for 110 lymphoblastoid 
cell lines from the tabulated GEUVADIS RNA-seq data (Express Array ID: E-GEUV-1)39. 
These samples (39 AFR and 77 EUR) match those for whom raw copy number variation data 
were available. We then used the non-parametric Kruskal–Wallis statistic to investigate the 
frequency of GSTT2 copy number variations and expression levels within these matched 
samples. 
Cell line and treatments cumene-hydroperoxide (cum-OOH). 
HET1A (an immortalized cell line from normal esophageal squamous mucosa) and HeLa 




Medium (DMEM)(Cat. No. 11965092) with 10% fetal bovine serum and 1% antibiotic-
antiseptic. Cells were plated in 35mm x 10mm polystyrene plates (Cat. No 430165)(Corning 
Incorporated, NY) with 4 coverslips (6mm) within the plate, at a starting number of 120,000 
cells per plate. For knockdown of GSTT2, four siRNAs (siRNA-05 
GCUAAGGAUGGUGAUUUC; siRNA-06 GCACCGUGGAUUUGGUCAA; siRNA-07 
AGGCUAUGCUGCUUCGAAU, siRNA-08 GACACUGGCUGAUCUCAUG, Darmacon) 
directed at GSTT2 were used at a concentration of 10nm. For controls, we use a non-target (NT) 
siRNA (10nm), as well as treated cells with just the OPTI-MEM plus RNAimax (mock 
control)(Invitrogen). Cells were plated and transfected using Lipofectamine® RNAiMAX 
Transfection Reagent (as directed by RNAiMAX protocol, Cat. No. 13778030(Thermo Fisher)) 
on day 1, with the following groups: mock, NT, si05, si06, si07, and si08. On day 2, we changed 
the media and proceeded to transfect again. Day 3; we changed the media and incubated cells for 
48hrs. After 48hrs, coverslips were transferred to a 24-well plate, cells when then treated with 
either 0µM or 100µM of cumene-OOH (247502 Sigma-ALDRICH) for 1hr. After treatment, 
fixed the cells for 20min at -20 °C using 100% cold methanol. After fixing, we washed the cells 
with PBS three times (5min) and incubated them in PBS at 4 °C until performing the 
immunofluorescence protocol.  
Over-expression of GSTT2 was performed using an OriGene construct for GFP (control) 
and GSTT2 (RC200040, NM_000854). HET1A cells were plated in 35mm x 10mm polystyrene 
treates plates at a starting number of 120,000 cells per plate. On day 2, cells were transfected 
using Fu-Gene transfection reagent at a 1:3 ratio. After 24hr transfection, media was changed, 
and cells were treated with 0µM or 100µM of cum-OOH for a 1hr period. Cells were fixed and 





On day 1, we removed the PBS and cross-linked the protein-DNA with 500µL of 10% 
phosphate buffered formalin for 20min at room temperature (RT). The cells were washed once 
with 500µL TBS followed by removal and the cells were permeabilized with 100% cold 
methanol (-20°C). After permeabilization, the cells were incubated for 1hr in a blocking buffer 
containing 5% goat serum, 1% BSA, and 0.2% Triton x100 in TBS (500µl of blocking buffer per 
well). We diluted the primary antibody (ɣ-H2AX 1:1500, GSTT2-1:500) in TBS with 1% BSA. 
150µL for each cover glass was used followed by incubation of the cells overnight at 4 °C, in a 
humidified chamber. The next day the cells were washed with TBS-T for 5min, 3 times. The 
cells were then incubated with secondary antibody for 1hr at room temperature (Alexa Fluor 488 
goat anti-mouse IgG1 (gamma1)(Cat. No. A21121); Alexa Fluor 594 goat anti-mouse IgG2a 
(gamma2a)(Cat. No. A21135)(Life Technologies)) at dilutions of 1:50 and 1:200 respectively, in 
1% BSA, followed by three 5min washes with TBS-T. Coverslips were mounted onto slides 
using DAPI mountain solution (Cat. No. P36935, Thermo Fisher) and stored at -20 °C prior to 
microscopic and photographic imaging.  
Western blotting. 
Cells were incubated and plated as described above (Treatments cum-H2O2 section). 
After 1 wash with PBS, 40ul of Cell Signaling protein lysis buffer (1X) with proteinase inhibitor 
cocktail (PIC)(20µl per mL) was added followed by scraping the plates. Lysates were transferred 
from the plates to a 1.5mL tube and spun for 20min at 4 °C. Supernatant was transferred to a new 
1.5mL tube followed by protein quantification using protein assay. All lysates for westerns were 
prepared at a 20µg concentration, with 20% 2-mercaptoethanol, and 4X sample buffer. Samples 




membranes were used and activated with 100% methanol for 1min. The transfer was performed 
using Novex Transfer Buffer, and run overnight at 12V. After transfer, membranes were stained 
with Ponceau red for assessment of transfer efficiency. Blocking was performed by incubating 
the membranes in 5% milk/TBST or 5% BSA/TBST for 1hr at room temperature. Primary 
antibodies [(GSTT2 (mouse monoclonal isotype IgG2a κ - Santa Cruz, Cat. No. 514667); γ-
H2AX (Anti-phospho-Histone H2A.X (Ser139) isotype IgG1 -Millipore, Cat. No. 05-636)] were 
diluted in 5% milk/TBST or 5% BSA/TBST and incubated over night at 4 °C. Membranes were 
then wash 3 times (5min per wash) with TBS-T.  Secondary antibodies were diluted in 5% 
milk/TBST and added to the membranes for 1hr incubations at room temperature. The 
membranes were washed 3 times with TBST, 5min per wash and then incubated with ECL for 
5mins before revealing using X-ray film.  
Indomethacin treatments. 
 Indomethacin (Cat No. I7378; Sigma-Aldrich) was diluted to 1M in 100% DMSO. 
Indomethacin (1M) was added to media use for HET1A (DMEM, 10% FBS) and diluted at 
concentrations of 300µM and 600µM. Since DMSO was used to dilute indomethacin, we use 
0.6% DMSO treated HET1A has control. After we added indomethacin to the media, we 
followed by an incubation in the water bath (37°C) for 1hr, or until indomethacin went into 
solution. 300,000 cells per well were plated on day 1 and incubated overnight for attachment. On 
day 2, media + indomethacin was added to the cells and left for the respective time points (6, 24, 
48, and 72hrs). 350µl of QIAzol Lysis Reagent (Qiagen, Valencia, CA) for mRNA, or 40 µl Cell 
Signaling protein lysis buffer (1X) with proteinase inhibitor cocktail (PIC)(20ul per mL) for 




collected. mRNA and protein extractions were performed on all samples following protocols, 
described above. 
Chromatin immunoprecipitation (ChIP). 
Chromatin immunoprecipitation was performed according to the methods of Gilfillan et 
al. 201240 and Krook et al. 201641. Summarizing, HET1A cells (3.0x105 per IP) were digested 
using Micrococcal nuclease (MNase) (70196Y, Affymetrix, Santa Clara, CA) for 5 minutes at 
37°C. Follow by sonication for 20 seconds (Qsonica cup horn sonicator (Qsonica Sonicators, 
Newtown, CT, USA)), blocked for 1 hour with Dynabeads A+G (10001D and 10003D; Life 
Technologies, Carlsbad, CA). After blocking, we proceeded to incubate with 1 µg of desired 
antibody concentrations overnight. The next day they were incubated with Dynabeads A+G for 3 
hours, washed (5 minutes wash; 5 x RIPA buffer, 1 x LiCl buffer, 1 x TE buffer), followed by 
digestion of proteins with Proteinase K for 1 hour at 55°C. Finally, we purified 
immunoprecipitated DNA according to manufacturer’s instructions (Zymo Genomic DNA Clean 
& Concentrator, D4011). Primer pairs for the GSTT2/2B promoter are listed in the appendix. 
ChIP antibodies were used as per manufacturer’s instructions; H3K4me3 Rabbit anti-Human 
Polyclonal Antibody (49-1005; Life Technologies, Carlsbad, CA), anti-trimethyl-Histone H3 
(Lys27) Antibody (07-449; Millipore, Billerica, MA), normal mouse IgG (sc-2025; Santa Cruz 











Figure 4.1. GSTT2 and GSTT2B expression in the NE of AA vs Cau (a) Array analysis of 
normal squamous esophageal tissue (NE) from AA and Cau reveals differential mRNA 
expression of GSTT2 (left panel) and GSTT2B (right panel), respectively. (b) Gene locus of 
GSTT2 and GSTT2B coding genes on chromosome 22 including GSTT family members GSTTP1 
and GSTT1. (c-e) Array analysis of normal squamous (NE) tissue from AA and Cau indicates 









Figure 4.2 GSTT2/2B mRNA array vs. qRT-PCR (a) Validation of GSTT2/2B expression in 
the NE of AA and Cau with and without Barrett’s (B) using qRT-PCR and with a larger cohort 
confirms differential mRNA expression of GSTT2/2B in AA vs. Cau (P=0.0031). (b) Pearson 







Figure 4.3 GSTT2/2B 17bp promoter duplication is associated with reduced mRNA 
expression (a) Two genomic events influence GSTT2/2B mRNA levels: a 37kb deletion that 
removes the GSTT2B gene, and the 17bp tandem GSTT2/2B promoter duplication. (b) The 17bp 
GSTT2/2B promoter duplication frequency is significantly lower in AA vs. both Cau and the 
AA:B and Cau:B disease populations by Fisher Exact test. (c) When all squamous samples are 
combined and analyzed (ANOVA) we observed that the 17bp promoter duplication shows a 
dose-dependent association with GSTT2/2B mRNA expression. (d) The combination of the 17bp 
GSTT2/2B promoter duplication plus the deleted GSTT2B genotype common to Cau have much 






Figure 4.4 GSTT2 promoter duplication genotype sequence in AA and Cau Examples of the 
GSTT2/2B 17bp duplication genotypes using reverse strand sequences showing (a) the alignment 















Figure 4.5 GSTT2 37kb deletion in AA vs Cau (a) GSTT2/2B locus structure showing the 37kb 
deletion that removes the GSTT2B locus. (b) Allele frequency of the 37kb GSTT2B deletion in 
NE of Cau and AA with disease (B) and without disease (NE). A trend towards an increased 
incidence of the deletion in Cau was noted (Fisher Exact). Comparisons involving AA-NE:B 
verse AA:NE or either Cau group were not significant. The comparison between Cau groups was 
also not significant. (c) When all squamous samples were combined a dose-related effect of the 
GSTT2B deletion on GSTT2/2B mRNA expression was suggested but did not reach statistical 
significance (Kruskal–Wallis test) because of low sample numbers. (d) The presence or absence 






Figure 4.6 1000 Genomes Data analysis of GSTT2/2B genotype and mRNA We used publicly 
available, matched RNAseq and DNA copy number data from cultured lymphoblasts from a 
subset of 1000 Genomes population controls (n=116) from normal African (AFR) and Caucasian 
(EUR) individuals that show: (a) the same trend as our esophageal NE samples of higher average 
GSTT2/2B expression in individuals of African descent. We also confirmed that both the (b) 
GSTT2/2B promoter duplication and (c) GSTT2B deletion have gene dose-related effects upon 
expression such that (d) individuals homozygous for the promoter duplication have much lower 







Figure 4.7 GSTT2/2B mRNA levels by gender, GERD history, and smoking status Using 
1000 Genomes population controls (n=116) we observe that differences in GSTT2/2B mRNA 
expression is not significantly different between (a) genders but is (b) race dependent. Within the 
40 arrayed NE samples differences in GSTT2 expression were not explained in terms of either 






Figure 4.8 GSTT2/2B promoter allele frequency among human populations (a) Frequency of 
GSTT2/2B promoter duplication and non-duplicated alleles in super populations (1000 Genomes 
data). (b) Frequency of the non-duplicated GSTT2/2B promoter is highest among African and 












Figure 4.9 HET1A and HeLa assesment of susceptibility to DNA damage with and without 
cum-OOH treatments (a) GSTT2/2B 37kb deletion and promoter duplication genotyping in a 
cohort of 12 cell lines. Bottom triangles highlight the HET1A and HeLa cell lines, respectively. 
Cells were quantified (400,000) and used to extract both mRNA and protein. (b-c) qRT-PCR and 
western blots were performed in HeLa and HET1A to measure endogenous GSTT2/2B and 
GSTT2 levels. (d) Quantification of positive foci γ-H2AX in HET1A and HeLa cells. A nuclei 
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Figure 4.10 Validation of GSTT2 knockdown in HET1A and HeLa cells (a-c) Relative 
GSTT2/2B mRNA expression in HET1A and HeLa cells after 48hr transfection with four 
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Figure 4.11 Knockdown of GSTT2 in HET1A and HeLa cells with and without cum-OOH 
treament (a-b) HET1A and HeLa cells were treateted with cum-OOH (0µM and 100µM)(1hr), 
DNA damage was assessed using immunofluorescence staining for γ-H2AX (green) and nuclei 
(DAPI). (c-d) Quantification of positive foci for γ-H2AX in HET1A and HeLa cells. A nuclei 













Figure 4.12 Knockdown of GSTT2 in HET1A and HeLa cells with and without cum-OOH 
treament (a-b) HET1A and HeLa cells were treated with cum-OOH (0µM and 100µM)(1hr), 
DNA damage was assessed using immunofluorescence staining for γ-H2AX (green) and nuclei 
(DAPI). (c) Quantification of positive foci γ-H2AX in HET1A and HeLa cells. A nuclei with 

















































































































Figure 4.13 HET1A over-expressing GSTT2 and following genotoxic stress (a) mRNA levels 
of GSTT2 in HET1A (qRT-PCR) cells and GSTT2 transfected (+ GSTT2) vs. control (GFP-
transfected cells). (b) Western blot of HET1A cells transfected with GSTT2 (+GSTT2)(top 
panel). (c) Western blot showing GSTT2 protein expression in HET1A treated with 0µM or 
100µM of cum-OOH for 1hr. (d) Dual immunofluorescence staining of GSTT2 (red) and γ-
H2AX in HET1A cells transfected with GSTT2, cells were treated with 100µM of cum-OOH for 
1hr. (nuclei staining is depicted in blue using DAPI). (e-f) quantification of foci formation in 






Figure 4.14 GSTT2 expression in AA vs Cau normal esophagus epithelium in GERD and 
non-GERD individuals (a) Western blot depicting GSTT2 expression in a cohort of AA and 
CAU normal esophagus, alpha-tubulin was used as loading control (b) Quantification of protein 
expression of GSTT2 in AA and CAU normal esophagus biopsies (GSTT2 expression in each 
sample relative to alpha-tubulin). (c) Genotype analysis was done by PCR, for the 37kb deletion 
(top panel: top band (~850bp) Non-Del; bottom band (~510) Deleted), and GSTT2/2B promoter 
duplication (bottom panel: top band (~317bp) DUP; bottom band (~300bp) Non-DUP). (d) 
Genotype for GSTT2/2B 37kb Deletion (-/-)(-/+) and non-deleted (+/+) associated with levels of 
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(-/-) associated with levels of GSTT2 protein. (f) Both genotypes matched to protein levels in 
GERD vs. No-GERD. 
 
 
Figure 4.15 HET1A treatment with Indomethacin (a) mRNA, (b) western, and (c) ChIP of 
HET1A after treatment with Indomethacin (300µM, 600µM), and DMSO (control). HET1A 
were treated with two different concentrations and samples were collected at different time 
points (6hr, 24hr, 48hrs, and 72hrs). ChIP experiment was performed using 600µM and 
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Table 4.2 All genes >2 FC between AA vs Cau (Affymetrix 2.1 ST Array) 































theta 2 0.0004 0.1372 0.0479 0.8557 5.15 2.17 0.39 0.92
IGHD
immunoglobulin heavy 
constant delta 0.0076 0.0307 0.0644 0.0039 5.07 0.21 0.29 7.24
IGHA1
immunoglobulin heavy 
constant alpha 1 0.0074 5.4E-06 0.0169 1.0E-06 3.77 0.05 0.27 21.53
GSTT2B
glutathione S-transferase 
theta 2B (gene/pseudogene) 0.0016 0.07 0.1038 0.5163 3.13 2.15 0.54 0.78
HLA-DPB1
major histocompatibility 
complex, class II, DP beta 1 0.0072 0.9458 0.6697 0.0486 3.13 1.03 0.82 2.5
MS4A1
membrane-spanning 4-
domains, subfamily A, member 
1 0.0054 2.8E-08 0.0194 2.0E-09 2.31 0.09 0.46 12.27
LOC643669 uncharacterized LOC643669 0.0003 0.0242 0.6023 0.655 2.13 1.73 0.89 1.1
MIR4518 microRNA 4518 0.0071 0.8133 0.3397 0.0731 2.11 0.93 0.75 1.71
*P-values	calculated	 on	Log2	values.	Fold	changes	(FC)		were	calculated	and	are	presented	 in	non-log	values.	
N
Age                     
>55 years 






BMI            
overweight
BE/EAC path       
diagnosed
(%) (%) (%) (%) (%) (%)
AA-NE 12 8 (67%) 12 (100%) 11 (92%) 2 (17%) 11 (92%) 0 (0%)
Cau-NE 12 5 (42%) 12 (100%) 10 (83%) 4 (33%) 11 (92%) 0 (0%)
AA-NE:BE 8 7 (88%) 5 (63%) 7 (88%) 8 (100%) 7 (88%) 8 (100%)
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Table 4.3 Promoter duplication allele frequency across world populations 

























African	Caribbean	 in	Barbados ACB AFR 96 135 50 0.73 0.27
African	Ancestry	 in	Southwest	US ASW AFR 66 46 10 0.82 0.18
Esan	in	Nigeria ESN AFR 99 157 32 0.83 0.17
Gambian	in	Western	Division,	The	Gambia GWD AFR 113 131 73 0.64 0.36
Luhya	in	Webuye,	Kenya LWK AFR 116 124 14 0.90 0.10
Mende	 in	Sierra	Leone MSL AFR 85 105 59 0.64 0.36
Yoruba	in	Ibadan,	Nigeria YRI AFR 116 110 40 0.73 0.27
Colombian	in	Medellin,	Colombia CLM AMR 95 109 21 0.84 0.16
Mexican	Ancestry	in	Los	Angeles,	California MXL AMR 69 43 0 1.00 0.00
Peruvian	in	Lima,	Peru PEL AMR 86 212 6 0.97 0.03
Puerto	Rican	in	Puerto	Rico PUR AMR 105 128 11 0.92 0.08
Chinese	Dai	in	Xishuangbanna,	China CDX EAS 99 213 10 0.96 0.04
Han	Chinese	in	Bejing,	China CHB EAS 106 190 8 0.96 0.04
Southern	Han	Chinese,	China CHS EAS 112 128 3 0.98 0.02
Japanese	in	Tokyo,	 Japan JPT EAS 105 156 6 0.96 0.04
Kinh	in	Ho	Chi	Minh	City,	Vietnam KHV EAS 101 247 6 0.98 0.02
Utah	residents	with	Northern	and	Western	
European	ancestry CEU EUR 103 162 5 0.97 0.03
Finnish	in	Finland FIN EUR 100 99 5 0.95 0.05
British	in	England	and	Scotland GBR EUR 94 115 2 0.98 0.02
Iberian	populations	in	Spain IBS EUR 107 161 15 0.91 0.09
Toscani	in	Italy TSI EUR 110 191 22 0.90 0.10
Bengali	in	Bangladesh BEB SAS 86 166 0 1.00 0.00
Gujarati	Indian	in	Houston,TX GIH SAS 106 152 15 0.91 0.09
Indian	Telugu	in	the	UK ITU SAS 103 148 7 0.95 0.05
Punjabi	in	Lahore,Pakistan PJL SAS 96 180 3 0.98 0.02
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Conclusion and Future Directions 
 
The incidence of esophageal adenocarcinoma (EAC) and gastro-esophageal junction 
adenocarcinomas (GEJAC) has increased at an alarming rate of >600% over the last five 
decades1,2. The increased incidence of EAC is one of the greatest observed for any frequent 
cancer type, and it is highly associated with the increased epidemic of obesity and 
gastroesophageal reflux disease (GERD). Furthermore, a recent study predicts that by the year 
2030, 1 in 100 Caucasians in the Netherlands and United Kingdom will be diagnosed with EAC 
in their lifetime3. The common risk factor, GERD, is now widely prevalent around the world. 
GERD is especially high in most developed countries/continents (North America, 
Australia/Oceania, Northern Europe)4. Other continents have started to observe a rise in GERD, 
mostly in Western and Southern Asia, as well as South America, making it a potential global 
concern4.   
Patients diagnosed with early stage EAC, have a favorable outcome when surgical 
resection or mucosal resection is performed5. Nevertheless, because the esophagus is highly 
vascularized, presentation beyond stage 1 is more likely to lead to metastasis, poor response to 
chemotherapeutics and radiation, as well as poor survival. Although many efforts have been 
made in implementing multimodal therapy, the 5-year survival rate for esophageal cancer 




early diagnostic-detection tools and preventive strategies to improve overall patient survival.   
EAC and GEJAC 
EAC is often associated with histological evidence of BE as compared to GEJAC8–10. 
Nevertheless, we observed that these two tumor types share many molecular characteristics at the 
mutation, copy number, and transcriptome level11,12. Because EAC is associated with the 
presence of BE, this has led to many efforts in surveillance protocols focused on early cancer 
detection in these patients13–17. GEJAC presents without BE, therefore, these individuals are 
unlikely to be considered for routine screening.  
Efforts have been made in improving the surveillance methods in the screening process 
of BE patients. One is the development of novel fluorescently-labeled peptides for endoscopic 
identification of early cancer in the esophagus18. In this thesis work, we have shown a strong 
similarity between Barrett’s-associated EAC and GEJAC. These data and identification of cell 
surface markers that are shared between these cancer types, suggests that peptides could be 
developed that would identify cancers of both the lower esophagus and GEJ, regardless of the 
presence of Barrett’s esophagus.  
We have recently demonstrated that TGM2 is overexpressed and present on the cell 
surface of EAC cells19. In addition, in this thesis work, we confirmed tumor-specific 
overexpression for three genes (CDH11, ICAM1, and CLDN3) using qRT-PCR, and 
demonstrated protein localization specific to the cell surface of tumor cells by IHC. The future 
goal of these markers will be to apply a multiplexed panel of peptides using multispectral 
scanning fiber endoscope technology20 to improve the success of histology-based screening 
programs for early EAC detection.  




EAC is known to arise from the pre-malignant BE tissue. Moreover, patients with high-
grade dysplasia (HGD) have a greater than 40% chance of developing EAC21. Therefore, HGD is 
the current gold standard for identifying “higher risk” of developing EAC in BE patients. In this 
thesis work, we have presented new insights into the transcriptome-based events that associate 
with increased risk of BE progression to EAC. We observed an increase in the splicing pathway, 
as well as an increase in transcript isoform diversity. This is likely to allow cells to increase their 
diversity of gene products and survive in a hostile environment. Concurrently, we observe a loss 
of protective mucin, and an increase in the ATM/DNA-damage response pathway (DDR). We 
further confirmed the activation of γH2AX by immunohistochemistry in HGD but not BE cells 
where mucin is lost and thus DNA damage is detected. Altogether, we surmised that increased 
spliceosome pathway during BE progression to EAC reflects both DNA damage and ATM-
dependent signaling events in dysplastic BE cells. Further mechanistic studies to understand the 
role of a diverse isoform variance in HGD/EAC might elucidate potential targets and treatment 
strategies for reducing the progression of BE to cancer.  
 Detection of HGD poses significant challenges. Since HGD is associated with a high risk 
of progression, yet, there are problems in regards to sampling error and inter-observer variability 
in its diagnosis. We pose the idea of developing targeted fluorescent peptides that are over-
expressed in the HGD when compared to non-dysplastic or low-grade dysplastic BE cells. In the 
current work, we have identified two markers, C3 and HLA-DRB5, as over-expressed in 
HGD/EAC. Nevertheless, dysplastic BE cells and EACs are heterogeneous22–24. Not every 
person with HGD over-expresses the same cell surface protein-coding genes. Therefore, we 
created an independent cohort of 160 high-risk patients with pathologically-confirmed HGD 




percentage of non-dysplastic BE, LGD or HGD in this independent cohort. In the future, it will 
be important to validate the expression levels using techniques that are effective and more 
clinically applicable than quantitative RT-PCR. If successful, candidates could be useful for 
identifying high-risk patients containing HGD in BE independent of pathologic assessment 
alone. 
 Protein localization and expression levels are imperative for understanding the validity of 
these cell surfaces markers. Although the Human Protein Atlas25,26 provides evidence that C3 
and HLA-DRB5 are abundant in GI cancers such as stomach cancers and are localized 
abundantly in the plasma membrane. Further, it will be necessary to validate this membrane 
expression in HGD and EAC tissue. We have made a formalin-fixed, paraffin-embedded tissue 
microarrays (TMA) containing duplicate cores from 100 patients with HGD that developed 
EAC. Using antibody’s against the candidate proteins of interest it will be important to assess the 
expression levels, the frequency of overexpression, and patterns of cell surface staining of these 
specific targets in the HGD/EAC.  
 Altogether these data highlight new insights into the molecular progression of BE 
dysplastic progression and identify potential biomarkers for detecting the highest risk epithelium 
HGD. In the future, we expect to develop better methods for early cancer detection and hopefully 
find new treatment modalities to improve patient survival with EAC.  
GSTT2 in the esophagus 
We have established that EAC primarily affects Caucasians with African Americans 
seemingly protected, despite both populations having a similar incidence of risk factors: obesity, 
and GERD27,28. In addition, African Americans have lower rates of esophagitis than 




African American and Caucasian normal esophageal tissues and identified glutathione S-
transferase theta 2 (GSTT2) as being the top over-expressed gene in the African American 
esophagus. In addition, we have shown that GSTT2 protects esophageal cells against DNA 
damage under genotoxic stress. Acid reflux has been shown to generate reactive oxygen species 
and can induce DNA double-strand breaks32. In the esophageal field, there is a lack of cell lines 
derived from normal squamous esophagus tissue. Currently, HET1A is the only cell line which 
was derived from the normal squamous epithelium of an American of African descent and was 
subsequently immortalized. Not only cell line number poses a problem for reproducibility of 
experimental approaches, but also the immortalization process produces caveats as to the true 
nature of a normal cell line vs. a transformed cell line. To better understand the processes that 
affect the normal squamous tissue and its response to acid reflux leading to DNA damage, it is 
imperative that we develop better models to study the normal tissue of the human esophagus. 
Recently, Mau et al. developed a system where they use a dual SMAD inhibition protocol for the 
long term expansion of different epithelial like tissues (such as pseudostratified, stratified and 
glandular epithelium)33. More specifically, they showed that they can expand and culture tissue 
from mice esophagus and these cells retain their ability to differentiate into stratified esophageal 
epithelium using an air-liquid interface (ALI) culture33. Mau et al. approach provides an 
opportunity to expand and maintain the human-derived normal esophageal tissue in culture, and 
in turn, examine the functional characterization of GSTT2 role in protecting this tissue against 
acid-induce DNA damage. 
Despite significant racial/population differences in EAC34, our ability to functionally 
explore these differences, investigate mechanisms leading to disease, design preventative 




derived from squamous esophagus tissue. We have established the importance of GSTT2 in 
protecting cells against genotoxic stress. Nevertheless, the methods used in this thesis, such as 
the knock-down using targeted siRNA, may introduce off target effects. In the future, it will be 
important to perform mechanistic studies involving genetic gain- and loss-of-function 
approaches to test the hypothesis that GSTT2 provides protection against genotoxic stress in both 
AA and Cau genetic backgrounds. For example, we could generate stable cell lines from AA and 
Cau genetic backgrounds that harbor genetically-inducible GSTT2, using tet-inducible lentiviral 
transduction or, use Crispr/Cas9 technology to generate GSTT2 knockout cell lines. These 
methods have the potential to elucidate GSST2 function in normal human tissue in vitro and in 
vivo.  
Finally, we show that GSTT2/GSTT2 is inducible using indomethacin (an NSAID), at the 
mRNA but potentially less so at the protein level. It has been reported that GSTT2 increases in 
the esophagus of rats when treated with NSAID.35 Non-steroidal anti-inflammatories (NSAIDs) 
have been independently shown that they can reduce the risk of EAC by >40% and induce 
GSTT236. Our results, together with the above rat studies, makes us hypothesize, that the type of 
model is important for understanding GSTT2 induction ability. Even further, it is unclear, the 
mechanism by which NSAIDs induce GSTT2. We have identified a binding motif within the 
promoter of GSTT2, for the transcription factor PPAR-gamma (Figure 5.1). Interestingly, it is 
known that PPAR-gamma is induced by indomethacin37. Therefore, future assessment of the 
effects of treatment of NSAIDs and polyphenols in affecting GSTT2 levels, and investigating 
whether this effect is mediated through the activation of the transcription factor (TF), PPAR-





Defining the mechanisms by which different human populations respond to injury/insult, 
will expand our understanding of EAC development and may provide avenues for new 



























Figure 5.1 PPAR-gamma DNA sequence binding motif (top panel) and BLAST results 
demonstrates region within the GSTT2 promoter where consensus sequence for PPAR-gamma is 





































Figure 5.2 Summary of thesis: Molecular characterization of esophageal adenocarcinomas and 
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Chapter Type Name Figure Primer Name Sequence 
2 cDNA CDH11 
Figure 2.12; 
2.13 CDH11-cDNA GCACGAGACCTATCATGCCA 
2 cDNA CDH12 
Figure 2.12; 
2.14 CDH12-cDNA CTGTCTGTGCTTCCACCGAA 
2 cDNA ICAM1 
Figure 2.12; 
2.15 ICAM1-cDNA GTA TGAACTGAGCAATGTGCAAG 
2 cDNA ICAM2 
Figure 2.12; 
2.16 ICAM2-cDNA GTTCCACCCG TTCTGGAGTC 
2 cDNA CLDN3 
Figure 2.12; 
2.17 CLDN3-cDNA  TCGGCCAACACCA TTATCCG 
2 cDNA CLDN4 
Figure 2.12; 
2.18 CLDN4-cDNA GTACTTCTTCTCGCGTGGGG 
2 cDNA ZNF217 Figure 2.8 ZNF217-cDNA  CTCCGGGCCACTTTACACTT 
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4.5; 4.9; 4.10; 
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4.5; 4.9; 4.10; 
4.13; 4.15 GSTT2 (E1-E2) CCAGGCTGTTGATCTGCAAG 
4 cDNA GSTT1 
 
GSTT1-cDNA CTGGAGTTTGCTGACTCCCTC 
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(ChIP) Figure 4.15 GSTT2_PromR_300 GCCCTGACCCAGAAACGACTG 
      
